Vorinostat (SAHA, MK0683)

Catalog No.S1047 Synonyms: SAHA, MK0683, suberoylanilide hydroxamic acid

Molecular Weight(MW): 264.3

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Cited by 103 Publications

Nature, 2017, 551(7679):247-250

PubMed: 29088702

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852

Nature, 2011, 471(7337):235-9

PubMed: 21390130

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062

Cell, 2014, 158(5):989-99

PubMed: 25131989

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096

Blood, 2013, 123(5):706-16

PubMed: 24319254

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543

Nat Commun, 2014, 5:3361

PubMed: 24553445

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061
J Exp Med, 2012, 209(1):35-50

PubMed: 22231305

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941

EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362

Clin Cancer Res, 2017, 23(12):3139-3149

PubMed: 27986747

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930

Clin Cancer Res, 2012, 18(14):3822-33

PubMed: 22623731

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994

Clin Cancer Res, 2011, 17(9):2819-29

PubMed: 21357681

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551

Proc Natl Acad Sci USA, 2013, 111(3):E364-73

PubMed: 24395801

Genes Dev, 2011, 25(24):2610-8

PubMed: 22016339
PLoS Biol, 2013, 12(1):e1001758

PubMed: 24409098

Cancer Res, 2012, 72(9):2251-61

PubMed: 22422937

Blood Cancer J, 2015, 5:e312

PubMed: 25978432

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545

Cell Death Differ, 2012, 19(8):1317-27

PubMed: 22322857

Int J Cancer, 2015, 136(11):2717-29

PubMed:

Int J Cancer, 2014, 135(7):1721-32

PubMed: 24615207

Int J Cancer, 2013, 132(9):2200-8

PubMed: 23024001

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245

Eur J Cancer, 2012, 48(7):1096-107

PubMed: 22154545

Oncogene, 2013, 33(33):4265-72

PubMed: 24292675
Oncogene, 2013, 32(10):1316-29

PubMed: 22543582

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed:

Cancer Lett, 2014, 351(1):50-8

PubMed: 24814395

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454

Diabetologia, 2012, 55(9):2421-31

PubMed: 22772764

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732

Cell Death Dis, 2013, 4:e733

PubMed: 23868066

Cell Death Dis, 2013, 4:e951

PubMed: 24309938
FASEB J, 2012, 26(7):3032-41

PubMed: 22459148

Acta Neuropathol Commun, 2015, 3(1):22

PubMed: 25853389

Mol Cancer Ther, 2014, 13(12):2784-92

PubMed: 25319394

Br J Haematol, 2015, 168(3):371-83

PubMed:

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed:

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed:

J Leukoc Biol, 2012, 91(5):701-9

PubMed: 22028329

J Transl Med, 2011, 9:37

PubMed: 21477288
J Biol Chem, 2015, 290(8):5028-40

PubMed:

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107

J Biol Chem, 2013, 288(35):25593-602

PubMed: 23878197

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624

J Biol Chem, 2012, 287(43):36609

PubMed: 22952229

Cancer Cell Int, 2014, 10.1186/s12935-014-0112-x

PubMed:

Mol Carcinog, 2013, 52(3):218-28

PubMed: 22121107

Mol Carcinog, 2012, 52(6):459-74

PubMed: 22308110

Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401

J Pharmacol Exp Ther, 2010, 86(16):8765-72

PubMed: 20739454

Proteomics Clin Appl, 2014, 8(11-12):924-31

PubMed: 25091122

Invest New Drugs, 2012, 30(2):541-7

PubMed: 21107885
Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462

J Alzheimers Dis, 2014, 41(4):1193-205

PubMed: 24844691

Retrovirology, 2011, 2(3):411-23

PubMed: 21966324

Cancer Biol Ther, 2014, 15(5):578-85

PubMed: 24556916

Pharm Res, 2012, 29(7):1960-76

PubMed: 22415140

BMC Cancer, 2015, 15(1):273

PubMed: 25880212

BMC Cancer, 2014, 14(1):373

PubMed: 24886166

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750

FEBS Lett, 2014, 588(9):1571-9

PubMed: 24607544

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006

PLoS One, 2013, 8(1):e53766

PubMed: 23320102
PLoS One, 2012, 7(9):e44265

PubMed: 22957056

PLoS One, 2012, 7(12):e52335

PubMed: 23272238

PLoS One, 2012, 7(12):e52753

PubMed: 23300762

PLoS One, 2011, 6(7):e22739

PubMed: 21818379

Chronobiol Int, 2012, 29(8):982-93

PubMed: 22891617

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086

Exp Dermatol, 2010, 19(12):1096-102

PubMed: 20629733

Biochem Biophys Res Co, 2012, 420(2):325-30

PubMed: 22425986

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.02.029

PubMed: 25746901

BMC Neurosci, 2011, 12:50

PubMed: 21615950

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548
Protein Expr Purif, 2012, 86(1):45-52

PubMed: 21992606

Oncotarget, 2017, 10.18632/oncotarget.15017

PubMed: 28157715

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420

Cytometry A, 2014, 85(1):78-87

PubMed: 24038859

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed:

Oncotarget, 2014, 5(15):5965-77

PubMed: 25115389

20 Customer Reviews

Activity of vorinostat in Jurkat and Peer T-ALL cell lines in an MTT cell viability assay. Cells were treated with increasing drug concentrations for 72 h. The data are plotted as the mean % of DMSO-treated control cells against the corresponding drug concentration. The error bars are the standard error. For each drug and cell line, 3-4 independent experiments were performed with 6 replicates at each drug concentration.

Nature 2011 471, 235-9. Vorinostat (SAHA, MK0683) purchased from Selleck.

Differential effects of HDAC inhibitors on histone and tubulin acetylation. Immunofluorescence analysis of histone H3 (K9ac/K14ac) and tubulin acetylation in HeLa cells treated for 4 h with vehicle, SAHA (10 μM), tacedinaline (50 μM), PCI-24781 (20 μM. (a) Mapping of histone acetylation in K562 cells treated with HDAC inhibitors by LC-MS/MS. Cells were treated with TSA (10 μM), SAHA (5 μM), PCI-24781 (2 μM), tacedinaline (50 μM) for 6 h. Histones were extracted from cells and acetylated peptides were quantified after isobaric tagging.

Nat Biotechnol 2011 29, 255-265. Vorinostat (SAHA, MK0683) purchased from Selleck.
Western blot analysis of histone H3 acetylation in the spleen of untreated and vorinostat-treated hNF-E2 tg mice (n = 4 of each genotype).

J Exp Med 2012 209, 35-50. Vorinostat (SAHA, MK0683) purchased from Selleck.

SAHA down-regulates c-FLIP expression and increases the sensitivity of CaP cells to undergo apoptosis in the presence of bicalutamide (A) Bar graph illustrating the sub-G0/G1 cell population in 22Rv1 (left panel) and LNCaP (right panel) cells in the absence and presence of 10μM bicalutamide, administered as a single agent or in ombination with increasing concentrations of the HDAC inhibitor, SAHA. (B) Immunoblots demonstrating the single agent activity of bicalutamide or SAHA, or effect upon their combined administration on the expression of c-FLIP and/or the processing of PARP. Equal protein loading was confirmed by GAPDH. (C) Bar graph illustrating the effect of bicalutamide and SAHA upon the induction of caspase-8 or caspase-3/7 activity in 22Rv1 cells (left panel) and LNCaP cells (right panel). (D) Immunoblots characterizing the impact of SAHA and/or bicalutamide upon the induction of PARP cleavage, in the absence or presence of the pan-caspase inhibitor, ZIETD. ZIETD was incubated with the cells for 12 h prior to the experiment. All data points shown in (A) and (C) represent the mean ± S.E.M. value, calculated from four independent experiments.

Clin Cancer Res 2012 18, 3822-33. Vorinostat (SAHA, MK0683) purchased from Selleck.
Analyses of efficacy, potency and IC50 of HDAC inhibitors point toward HDACs 1–3 as relevant candidates for beta cell protection. Ranking and raw data on ITF drugs (Table 3) and commercial HDAC inhibitors (Table 4) underlying the heat maps of Fig. 1 (A and B). The HDAC inhibitor compounds were tested using a HDAC activity kit and recombinant proteins to determine IC50 values on each individual HDAC (right part of the table). Each drug was further tested using Real-Time Cell Analysis (RTCA) to score their maximal effective concentration (ECmax) as well as the corresponding rescue percentage of cytokine treated INS-1 cells. The drugs were ranked according to % rescue. * DMSO alone controls were included in each experiment, but not shown here. The results indicate that the highest concentrations of DMSO used here (1:1,000) were slightly potentiating the proliferation of the cells. The effects observed in this group of compounds were ascribed to the DMSO.?

Diabetologia 2012 55, 2421-2431. Vorinostat (SAHA, MK0683) purchased from Selleck.

Suberoylanilide hydroxyamic acid (SAHA) preserves CFP (+) expression in mouse optic nerves (MONs) from older mice. (a) CFP (+) mitochondria were longer and thicker in MONs from 12-month-old Thy-1 CFP mice (inset; scale bar = 2 μm). Oxygen–glucose deprivation (OGD) consistently reduced CFP pixel intensity in 12-month-old MONs despite longer and brighter CFP ( +) mitochondria (yellow arrows). (b) Blockade of AMPA/kain ate receptors with NBQX (30 μM), or pan-Histone deacetylase (HDAC) inhibition with SAHA (5 μM), effectively preserved CFP pixel intensity during OGD. The preservation of CFP (+) mitochondria correlates with protection of the CAP area during OGD and profound recovery.

J Neurochem 2012 123 Suppl 2, 108-15. Vorinostat (SAHA, MK0683) purchased from Selleck.
D and E, Regression of IL-13Ra 2-negative pancreatic tumors treated with SAHA and/or IL-13-PE. Mice were treated daily with i.p. injection of SAHA (25 mg/kg) from day 4 after tumor implantation for two weeks followed by i.t. injection of IL-13-PE (100 μ g/kg) from day 5 for two weeks. F and G, Regression of IL-13Ra 2-posotive pancreatic tumors (HS766T and MIA-PaCa2) treated with SAHA and/or IL-13-PE. The schedule of treatment was similar as in panel D and E. Statistical significances are shown by *: P < 0.05,†: P < 0.001.

J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.

IL-13Rα2 expression is upregulated in pancreatic tumors but not in organs of mice after treatment with HDAC inhibi tor, SAHA. A, qRT-PCR of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. Tumors were harvested next day after IL-13-PE treatment and total RNA extracted. Data shown is ratio of human IL-13Rα2/β-actin expression and multiplied by 1000 for convenience. Bars , SD of triplicate determinations. B, qRT-PCR of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Tissues were harvested at the same time point as in panel A and total RNA extracted. Data shown is ratio of mouse IL-13Rα2/β-actin expression and multiplied by 100 for convenience. C, IHC of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. D, IHC of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Liver, brain, kidney, pancreas, lung and spleen were fixed for immunostaining of mouse IL-13Rα2 as visualized by Alexa555. Nucleus was counterstained by DAPI.

J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.
Proliferation o f HT29 and HCT116 cells after 48 h of butyrate or SAHA treatment. Proliferation measurements using the xCEL Ligence RTCA DP instrument (Roche) in cells treated with increasing doses of butyrate or SAHA, compared with control medium cells (0) (*P < 0.05). The mean ?SEM of three cell culture replicates is shown.

Mol Carcinog 2012 52, 459-74. Vorinostat (SAHA, MK0683) purchased from Selleck.

SAHA induces the down-regulation of cFLIP expression and promotes TRAIL-mediated activation of a mitochondrial-operated apoptotic pathway. a BT-474 cells were treated as indicated in Fig. 1 and the cells were then harvested to analyse caspase-8, Bid, caspase-9, caspase-3 and PARP expression, using GAPDH as the protein loading control. b BT-474 cells were treated with SAHA for 8 h at the doses indicated and subsequently, the cells were harvested and the apoptosis-related proteins were analysed in western blots as described in the "Materials and Methods". The results shown are representative of at least three independent experiments

Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.
Treatment with SAHA sensitizes breast cancer cells to TRAILinduced apoptosis. BT-474 and MDA-MB-231 cells were incubated for 8 h with SAHA at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some of the cultures for an additional 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content as described in the "Materials and methods". The results show the mean and S.E.M. of three independent experiments

Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

SAHA facilitates the Itch/AIP4-independent proteasomal degradation of cFLIP proteins in breast cancer cells. a BT-474 cells were treated with SAHA (5 μM) for 8 h in the presence or absence of the proteasome inhibitors MG132 or epoxomicin (at the doses indicated), and they were then harvested and the cFLIP content was analysed in western blots. b BT-474 cells were transfected with either the siRNA oligonucleotides targeting Itch/AIP4 or the non-targeting RNA oligonucleotide (scrambled) for 48 h as described in the "Materials and Methods". Subsequently, the cells were treated with SAHA (5 μM) for 8 h and then cFLIP and Itch/AIP4 expression was analysed in immunoblots

Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.
cFLIP down-regulation following SAHA treatment is responsible for the sensitization of breast cancer cells to TRAIL. a BT-474 cells were transfected with either different siRNAs directed against the cFLIP isoforms or the non-targeting RNA oligonucleotide (scrambled) as described in the "Materials and Methods". After 24 h, the cells were treated with TRAIL (500 ng/ml) for a further 15 h and apoptosis was then measured as the percentage of cells with subG1 DNA content. The results show the mean and S.E.M. of three independent experiments. To verify protein knockdown, cells were harvested 24 h after transfection and the cFLIP levels were assessed in immunoblots. b. BT-474 cells overexpressing Cflipl (pBABE-FLIPL) or control cells (pBABE) were treated with SAHA for 8 h at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some cultures for 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content and the results show the mean and range of two independent experiments. Western blots show the cFLIP levels after SAHA treatment in pBABE and pBABE-FLIPL cells.

Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

Vorinostat inhibits the tumor growth. NOD ⁄ SCID-B2m^-/-mice were injected s.c. with 1×10⁶ MyLa2059 cells into both flanks. When the mice had developed established palpable tumors treatment was initiated (day 1). The mice received either vehicle (black line) or 60 mg ⁄ kg vorinostat (grey line) i.p. five days a week. In total, there were four mice in the group receiving vehicle and three mice in the group receiving vorinostat. The length and width of the tumors were measured continuously until the experiment was terminated on day 20 post treatment initiation. The tumor volume was calculated using the formula V = (a×b²)/2, where a defines the length (mm) and b the width (mm) of the tumor. The histogram shows the average tumor volume per flank ± SEM. * denotes a significant difference (P < 0.05) in the average tumor volume per flank between mice treated with vehicle and vorinostat at the given time-point both by using a one-tailed two samples test with Welch^,scorrection and a Mann-Whitney U test.

Exp Dermatol 2010 19, 1096-1102. Vorinostat (SAHA, MK0683) purchased from Selleck.
(a) Western blot of whole cell extracts demonstrates SAHA and NaB treatment result in increased levels of acetylated histone H3 compared to vehicle controls. (b) Light micrographs of HDACi/vehicle treated cultures illustrate the paucity of neurospheres in HDACi-treated cultures. (c) Quantitative analysis confirms SAHA and NaB inhibit the formation of neurospheres (diameter ≥ 50 μm) and increase the prevalence of small cell clusters (≥ 4 cell, diameter < 50 μm). (d) Flow cytometry using LIVE/DEAD cell stain confirms SAHA and NaB are minimally toxic compared to vehicle controls (n = 3). Scale bar = 100 μm.

BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

(a) EdU flow cytometry of live cell-gated adult mouse NSCs demonstrates SAHA (**p < 0.01) and NaB (***p < 0.001) significantly inhibit DNA synthesis. (b) Analysis of DNA content by flow cytometry reveals significant accumulation of adult mouse NSCs in G1phase of the cell cycle following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (c) Correspondingly the proportion of cells in G2/M phase is significantly reduced following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (d) Fluorescence micrographs of HDACi/vehicle treated adult NSCs pulse-labeled with EdU for flow cytometry. Scale bar = 50 μm. Statistical comparisons performed using one-way ANOVA with post hoc Newman-Keuls multiple comparison tests.

BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.
(a) Immunofluorescence labeling of NeuN, GFAP and Olig2 cell fate markers reveals reduced expression of GFAP (*p < 0.001) and Olig2 (*p < 0.05) in adult mouse NSCs treated with SAHA for 48 hours under proliferation culture conditions and then induced to differentiate for 14 days in culture (two-way ANOVA with Bonferroni post-tests). (b) Western blot of β-catenin protein in nuclear and cytoplasmic fractions of adult mouse NSCs treated with HDACi/vehicle control under proliferation culture conditions. Gapdh and lamin A/C blots are included as loading controls. (c) SAHA and NaB do not significantly alter nuclear/cytoplasmic levels of β-catenin in adult mouse NSCs. Histogram of β-catenin Western blot signal intensities normalized to loading controls (n = 4).

BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

Morphological changes and histone H3 phosphorylation of HB cells treated with a combination of VX-680 and SAHA. HUH6 and HepT1 were incubated with VX-680 (6 μM) and SAHA (0.5 μM). Nuclei diameter (a) and cell diameter (b) were determined 72 h later by DAPI staining and microscopy. Data represent mean±SD of the diameters from 20 cells in each experiment. (* Two-way ANOVA, Bonferroni test, p \0.05). c Western blot analysis on HUH6 and HepT1 cells were carried out with an anti-phospho-Histone H3 (Ser 10) antibody (p-H3) 24 h after incubation with VX-680 (10 μM), SAHA (0.2 μM) or a combination of both. Controls were left untreated. Western blot analysis showed a decrease in p–H3 after treatment with VX-680 ( lane 2 ) relative to controls ( lane 1 ) and an increase when SAHA was added ( lane 3 ). For the combination of VX-680 and SAHA (lane 4 ) no p-H3 was detected.

Pediatr Surg Int 2012 28, 579-89. Vorinostat (SAHA, MK0683) purchased from Selleck.
Vorinostat promotes C2C12 differentiation.In the image, the red is the myotube indicating differentiation ,the blue is the nuclei.

Dr. Akihiko Yoshimura of Akihiko Yoshimura. Vorinostat (SAHA, MK0683) purchased from Selleck.

Western blot analysis of Acetyl-H3 and H3. 0-20μM SAHA was added.

Dr. Zhang of Tianjin Medical University. Vorinostat (SAHA, MK0683) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Targets

HDAC ^[1]
(Cell-free assay)

~10 nM

In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. ^[1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. ^[2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. ^[3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A20	MmTiT4lv[XOnIFHzd4F6		M4G4dlEhcA>?	M3LibWROW09?	NVLm[I5J[W62aT3ISGFEOSCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yOTJizszN	MlzhNVE6PjB2OEm=
Friend leukemic cell	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX21NYJEPTBizszN	NULJVWsxPzJiaB?=	NF7GW\|NFVVOR	NGXiWllKSzVyPUCuPVkh\|ryP	MXyxNlExQTlzMx?=
K562	M3;sZmtqdmG\|ZTDBd5NigQ>?		NYq3XXlNPiCq	NH;tbndFVVOR	NV3NT4JnUW6qaXLpeIlwdiCxZjDoeY1idiCqaYP0c45mKGSnYXPleJlt[XOnIDjtbZh1fXKnIH;mJGhFSUNzIHHu[EBJTEGFMjmge4l1cCCLQ{WwJI9nKDBwMEGg{txO	NF23W\|MyOjRzOUO4NC=>
HT1080	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmDZO\|IhcA>?	MWnEUXNQ	M3WxUWlEPTB;Mj60JO69VQ>?	MoC5NVIzPzBzN{W=
H1299	Mlv2T4lv[XOnIFHzd4F6		NFPhbmQzOCCvaX6=	NWrYc21QTE2VTx?=	NWPEbVRNUW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KEiGQVOg[Y57gW2nIIfpeIghUUN3MDDv[kAxNjF7NDFOwG0>	NFfvPYMyPDV{MUSyNi=>
H1299	MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHu2[IM4OiCq	NVf5[HF2TE2VTx?=	NWrh[lExUUN3ME23MlI1KM7:TR?=	MlnLNVQ2OjF2MkK=
HeLa	NGjINFVMcW6jc3WgRZN{[Xl?		NE\LdnI{OCCvaX6=		NXL6Sm52UW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgbIl{fG:wZTDk[YFk\XS7bHHz[UB4cXSqIFnDOVAhd2ZiMD6yPEDPxE1?	NYLFTFRjOTV4MEO5OFk>
LOX-IMVI	MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4e5U\|Q5KGh?		NFPKNohKSzVyPUGuN{DPxE1?	NXy2UZBkOTV5MUW0O\|A>
NCI-H226	NWXuN2N4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUC0PEBp		NWLOOoNGUUN3ME2yMlYh\|ryP	M{CzVVE2PzF3NEew
RXF-631L	M1H4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlnLOFghcA>?		MnjOTWM2OD1{IN88US=>	M4nQNlE2PzF3NEew
SNB-78	M1P0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{DjVFQ5KGh?		NGPFSnJKSzVyPUG2JO69VQ>?	MUSxOVcyPTR5MB?=
St-4	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NICxZYs1QCCq		NY\NUHduUUN3ME21MlIh\|ryP	M2CweFE2PzF3NEew
ARP1	MXzGeY5kfGmxbjDBd5NigQ>?	NX7obmlEOiEQvF2=	M122eVYhcA>?		NHrqOWpKdmS3Y4Tpc44hd2ZiUEKxW2FHOSCpZX7lJIV5eHKnc4Ppc44>	NWS3cXVEOTR5M{S4NFY>
CEM	MmToT4lv[XOnIFHzd4F6		NV7wTZpIOSCq	NEL2RVNFVVOR	MlviTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkOzJO69VQ>?	NHXNTZQyPjR{MEC2OC=>
HCT15	MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MW[0PEBp		NEXPN5NIUTVyPUCuPFIh\|ryP	NHTITlAyPjd{M{KyOy=>
NCI-H23	NG[0OodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH\kRVM1QCCq		NEjSbndIUTVyPUCuPVIh\|ryP	M1u4V\|E3PzJ\|MkK3
GM15850	NH7ITYJMcW6jc3WgRZN{[Xl?	NGftXWszNjVizszN	M{S4Zlk3KGh?	MlvDSG1UVw>?	MVHJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDsfZNqdmViMUSgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	M1:1dFE3QTJzM{[3
GM15850	NW[yRVhGU2mwYYPlJGF{e2G7	MYWyMlUh\|ryP	M{PzUFk3KGh?	NGraSIpFVVOR	MXnJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViNTDhZ4V1gWyjdHnvckBw\iCIWF6g[4Vv\Q>?	NWLkeHRFOTZ7MkGzOlc>
GM15850	MWfLbY5ie2ViQYPzZZk>	MWWyMlUh\|ryP	NFnFcW06PiCq	NIHn[4RFVVOR	MWjJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViMUKgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	NVvOSYZHOTZ7MkGzOlc>
GM15850	MkflT4lv[XOnIFHzd4F6	MnnINk42KM7:TR?=	NU\yeHBTQTZiaB?=	M{LqcGROW09?	MoGxTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSEOgcJl{cW6nIEmgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	M13kNFE3QTJzM{[3
GM15850	M1rEOGtqdmG\|ZTDBd5NigQ>?	NYT4To5mOi53IN88US=>	M{H0NVk3KGh?	M3:3[mROW09?	NHXyZo9KdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgPEBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	NF3NR24yPjl{MUO2Oy=>
GM15850	M4rkeWtqdmG\|ZTDBd5NigQ>?	MlTxNk42KM7:TR?=	MXi5OkBp	NXjBSpVVTE2VTx?=	Mny4TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEG2JIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n	NXLFNYF3OTZ7MkGzOlc>
U937	MXzGeY5kfGmxbjDBd5NigQ>?	NHLYXGc2KM7:TR?=	MojVNlQhcA>?	NV24R3lzTE2VTx?=	M3;NemNmdGxiY4njcIUh[XK{ZYP0JIJ6KGGlY4XteYxifGmxbjDheEBUN0d{L12gdIhie2V?	MWCxO\|AxPDdzOB?=
H661	NGWxN2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlXUOFghcA>?		NUn4NlY4UUN3ME2xJO69VQ>?	NX60PYtCOTdzNUewNFk>
U937	NUHxW2gzTnWwY4Tpc44hSXO\|YYm=	M{HWVlUh\|ryP	M{jNW\|I1KGh?	MWTEUXNQ	NVnuNHF{UW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDhZ4V1gWyjdHnvci=>	MnjZNVc1PDd5NUC=
U937	M{[3eWZ2dmO2aX;uJGF{e2G7	NYXBbog3OSEQvF2=	Ml\mNlQhcA>?	MlvvSG1UVw>?	NFi2e\|BG\m[nY4Sgc44h[WyyaHGgeJVjfWyrbjDhZ4V1gWyjdHnvci=>	M2DhWlE4PDR5N{Ww
RAW264.7	NYixXGdCTnWwY4Tpc44hSXO\|YYm=	M1HOfVExKM7:TR?=	M3j1WlI1cA>?	MXj3ZZRmeg>?	MVfJcohq[mm2aX;uJI9nKEySUz3zeIlufWyjdHXkJHRPTmGucHjhJJBzd2S3Y4Tpc44hf2m2aDDJR\|UxKG:oIECuO\|Yh\|ryP	MWixO\|Q4PzVzOB?=
RAW264.7	NGHS[WFHfW6ldHnvckBCe3OjeR?=	NGf6S28yOCEQvF2=	MXGyOIg>	NXHiVnFSf2G2ZYK=	MlyzTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBPVyCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAyNjh6IN88US=>	MVSxO\|Q4PzVzOB?=
SC9	NFjDRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn3TOFghcA>?		MXjJR\|UxRTBwNkC2JO69VQ>?	Mo\rNVc2ODd{MUm=
ST14A	MXTGeY5kfGmxbjDBd5NigQ>?	MY[1JI5O	MnzGO\|IhcA>?		MYDJcoNz\WG\|ZTDpckBTTVOWL17SV2YhdVKQQTDlfJBz\XO\|aX;u	NX36XGVZOTd3NkW5PVM>
ST14A	NFraWmhHfW6ldHnvckBCe3OjeR?=	MX21JI5O	M1j5eFczKGh?		M1K2XWlv[3KnYYPlJIlvKEV{RkGgcXJPSSCneIDy[ZN{cW:w	NEfsTWYyPzV4NUm5Ny=>
PANC1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\XNlEh\|ryP			MULJR\|UxRTBwNEWg{txO	MWWxO\|U5QDd2NB?=
PANC1	NVG3[pdWTnWwY4Tpc44hSXO\|YYm=	M1HRdlEh\|ryP	M{jidFI1KGh?		NILCUIpKdmO{ZXHz[UBqdiCyMkHXRWYyN0OLUEGg[4Vv\SCneIDy[ZN{cW:w	MkDmNVc2QDh5NES=
PANC1	M1\mS2Z2dmO2aX;uJGF{e2G7	MXGxJO69VQ>?	MoTiNlQhcA>?		NYDl[2hxUW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44>	NUe3TIlLOTd3OEi3OFQ>
PT45	NHHDOJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfI[G9KSzVyPUSg{txO	MUCxO\|U5QDd2NB?=
ACHN	MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYmyNUBp		NWjvSYxpT0l3ME2wMlY2KM7:TR?=	NYr4TlB1OTd4NkK2NFY>
PC3	NF73XHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn\xNlEhcA>?		MX7HTVUxRTBwN{Gg{txO	NX3CVGljOTd4NkK2NFY>
A431	MVPDfZRwfG:6aXOgRZN{[Xl?		MWK3NkBp		M{TPS2lEPTB;ND6yJO69VQ>?	MmPiNVc3QTF5NkO=
Cal27	MVfDfZRwfG:6aXOgRZN{[Xl?		MUm3NkBp		NVfwVmYxUUN3ME2zMlIh\|ryP	MYGxO\|Y6OTd4Mx?=
CCRF-CEM	MoqyR5l1d3SxeHnjJGF{e2G7		NHTSN4Q4OiCq		MlXKTWM2OD1yLkig{txO	NIjnU3IyPzZ7MUe2Ny=>
EOL1	MlzxR5l1d3SxeHnjJGF{e2G7		NGj1U3I4OiCq		MVnJR\|UxRTFizszN	MVOxO\|Y6OTd4Mx?=
Hec-1-A	NGrQNmhEgXSxdH;4bYMhSXO\|YYm=		NHfh[Jg4OiCq		MWrJR\|UxRTFizszN	MVuxO\|Y6OTd4Mx?=
HeLa	MWLLbY5ie2ViQYPzZZk>	Mkf1NVAh\|ryP	NHrTO4M{OCCvaX6=	NGTsepNFVVOR	NHnNcm9KdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGhFSUNzIIfpeIghUUN3MDDv[kAxNjB{IN88US=>	NHjQO20yPzZ7MUe2Ny=>
RKOp21	NHLqXJREgXSxdH;4bYMhSXO\|YYm=		MlHDO\|IhcA>?		MWnJR\|UxRTFwN{[g{txO	Mn\iNVc3QTF5NkO=
Saos2	NFi3S5VEgXSxdH;4bYMhSXO\|YYm=		NHmwOYg4OiCq		NHzVfHRKSzVyPUKuN{DPxE1?	M{eyZlE4PjlzN{[z
SK-OV-3	M{jTd2N6fG:2b4jpZ{BCe3OjeR?=		NH\OXIs4OiCq		M{G5VGlEPTB;Mj6yJO69VQ>?	M3H6[\|E4PjlzN{[z
U87MG	M{joSGN6fG:2b4jpZ{BCe3OjeR?=		NYnsbFIyPzJiaB?=		NWL1U29qUUN3ME2xNUDPxE1?	MYixO\|Y6OTd4Mx?=
NUGC3	NHrZeW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\zc3M2KM7:TR?=	MkL6NlQhcA>?		NIDUN2JIUTVyPUKuO\|kh\|ryP	M1;CW\|E4QTB2OESz
CCD1059SK	M2DaWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7PTWM2OD12Mz61JO69VQ>?	M4PNXlE5OjR5NUW0
HepG2	NITYOW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTBwMECwOkDPxE1?	M2TLWFE5OjR5NUW0
HT1080	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\zTWM2OD1yLkCwNlQh\|ryP	M1;BWVE5OjR5NUW0
SKBR3	NITERWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLETWM2OD1yLkig{txO	MkHGNVgzPDd3NUS=
SNB78	M163dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLxSWM2OD1zNjFOwG0>	M2nadFE5OjR5NUW0
SQ20B	MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TNeGlEPTB;MzFOwG0>	MXOxPFI1PzV3NB?=
St4	NF7IbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjWVo51TUN3ME21MlIh\|ryP	MV:xPFI1PzV3NB?=
MCF7	MV7GeY5kfGmxbjDBd5NigQ>?	NUDZbpV6OTBizszN	MUe4JIg>	MmjUSG1UVw>?	NYHRZoJtUW6mdXP0bY9vKG:oIIT1ZpVtcW5iaInw[ZJi[2W2eXzheIlwdg>?	NVPOO29sOTh{NkmyNlY>
HEK293	MUXLbY5ie2ViQYPzZZk>		NYLs[2JKOSCq	NG\ORpdFVVOR	Mnv3TY5pcWKrdHnvckBw\iCKRFHDNUB4cXSqIFnDOVAhd2ZiMD6wN{DPxE1?	MnPKNVg{ODh3NkO=
HEK293	M3vXfWtqdmG\|ZTDBd5NigQ>?		NYH5OGZDOSCq	MV7EUXNQ	NFvqWpJKdmirYnn0bY9vKG:oIFjERWM{KHerdHigTWM2OCCxZjCwMlA2PyEQvF2=	MlHvNVg{ODh3NkO=
G401	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUC3NkBp	MXXEUXNQ	MkLXTWM2OD1zIN88US=>	MUmxPFM4ODN5Mx?=
HeLa	NHHZNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUn4fHZzPzJiaB?=	MkPZSG1UVw>?	M4nRUmlEPTB;MD60OkDPxE1?	NIXKfokyQDN5MEO3Ny=>
Human renal epithelial cell	NHW4d21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX63NkBp	NYLEfXc1TE2VTx?=	MlTmTWM2OD1zNDFOwG0>	MUixPFM4ODN5Mx?=
U937	M{i5bmZ2dmO2aX;uJGF{e2G7	NFLmXZM2KM7:TR?=	NGXFNlYzPCCq		Mk\JTY5lfWO2aX;uJI9nKGirc4TvcoUhUDRiaInw[ZJi[2W2eXzheIlwdg>?	M4DHTlE5OzhzMkO4
U937	NILtWVhHfW6ldHnvckBCe3OjeR?=	MX21JO69VQ>?	MXqyOEBp		NIDrSpVKdmS3Y4Tpc44hd2ZiYXzwbIEhfHWkdXzpckBpgXCncnHj[ZR6dGG2aX;u	NHz6PWYyQDN6MUKzPC=>
U937	NWPlfGxsTnWwY4Tpc44hSXO\|YYm=	NX3Yd5p{PSEQvF2=	MXKyOEBp		NVLRRo9qUW6mdXP0bY9vKG:oIICyNUBmgHC{ZYPzbY9v	NI[wSpkyQDN6MUKzPC=>
U937	MnHXSpVv[3Srb36gRZN{[Xl?	MmmyOUDPxE1?	M37XRlI1KGh?		NGLQcnRKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|	Mk[5NVg{QDF{M{i=
U937	NWL1U\|QyTnWwY4Tpc44hSXO\|YYm=	NYnITm9QPSEQvF2=	NHyy[FMzPCCq		MVvJcoR2[3Srb36gc4Yh\3KjboXsc4N6fGmlIHTp[oZmemWwdHnheIlwdg>?	M3PvVlE5OzhzMkO4
U937	NW\zcI1jU2mwYYPlJGF{e2G7	M2Pnc\|Uh\|ryP	MUeyOEBp		NGfjNI1KdmirYnn0bY9vKG:oIHj1cYFvKEiGQVOx	M33tflE5OzhzMkO4
U937	NYPiR4lyU2mwYYPlJGF{e2G7	NUHkb45xPSEQvF2=	NIHFeGgzPCCq		M3:4UWlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{S=	M2HXU\|E5OzhzMkO4
HEK-TE	M4rqW2Z2dmO2aX;uJGF{e2G7	Mor1OUDPxE1?	M331XFZp	NHTuUI1FVVOR	MU\JcoNz\WG\|ZTDpckBpcXO2b37lJGg{KGGlZYT5cIF1cW:w	MYexPFQ{PDF2NB?=
HPDE6c7	M4rqO2N6fG:2b4jpZ{BCe3OjeR?=	MX61NEDPxE1?	NHLr[VE4OiCq	NVX5UW5PTE2VTx?=	M{jlZ2lEPTB;MT6zJO69VQ>?	M3zkNFE5PDl2NE[z
Human microvascular epithelial cell	Ml:0R5l1d3SxeHnjJGF{e2G7	M2HD[\|UxKM7:TR?=	M4C3S\|czKGh?	NXnQ[ZEyTE2VTx?=	NYq2V3Y5UUN3ME2xMlMh\|ryP	NW[zW4xJOTh2OUS0OlM>
Hup T3	MlTTR5l1d3SxeHnjJGF{e2G7	M{ewdVUxKM7:TR?=	NWjmfGhEPzKq	NXzTXHAzTE2VTx?=	MUfJR\|UxRTBwODFOwG0>	Mnz0NVg1QTR2NkO=
Mia Paca2	M3PGSGN6fG:2b4jpZ{BCe3OjeR?=	MmLsOVAh\|ryP	M{\Lb\|czcA>?	NWjSR4xsTE2VTx?=	MlznTWM2OD1zLkGg{txO	MV2xPFQ6PDR4Mx?=
Panc 04.03	NXXRTmt5S3m2b4TvfIlkKEG\|c3H5	M3P2Z\|UxKM7:TR?=	MWK3Nog>	NE\VdY5FVVOR	MkPpTWM2OD1zLkKg{txO	Mn;qNVg1QTR2NkO=
SU 86.86	MU\DfZRwfG:6aXOgRZN{[Xl?	Mn7xOVAh\|ryP	M{HRR\|czcA>?	MknSSG1UVw>?	NWS0Rox5UUN3ME2xMlMh\|ryP	MVWxPFQ6PDR4Mx?=
HEK293	MmPxT4lv[XOnIFHzd4F6		MUCzJIg>		MXTJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFjERWM3KGW6cILld5Nqd25id3n0bEBKSzVyIH;mJFAvODF7IN88US=>	M1fqPFE5PTV6Nk[5
HeLa	NEP6bJNMcW6jc3WgRZN{[Xl?		NUHEcpAxOiCq		MV7Jcohq[mm2aX;uJI9nKG63Y3zlZZIhUESDQzD3bZRpKEmFNUCgc4YhOC5yOEOg{txO	MYixPFU2QDZ4OR?=
RAW264.7	NYLuNJlTTnWwY4Tpc44hSXO\|YYm=	MYCyJO69VQ>?	NWP6bnZHOy53IHi=	NX7adI02TE2VTx?=	MVPBcpRqdWGuYYLpZYwh[WO2aY\peJkh[WejaX7zeEBRdGG\|bX;kbZVuKG[jbHPpdIFzfW1iaX7m[YN1\WRid3n0bEBKSzVyIH;mJFAvOTFizszN	NULke3RKOTh4NES5Olk>
NB4			MlPuOFhp	MljHSG1UVw>?	MVLJR\|UxRTBwNjFOwG0>	NWHYPJVQOTh5MkOzOFk>
HEK293	NYrxOVZJTnWwY4Tpc44hSXO\|YYm=	NWixWYN[OTBizszN	M1:0VlI1KGh?	NWiyZ\|V1TE2VTx?=	M1iwNmFkfGm4YYTpc44hd2ZibX;1d4UhX262M3Ggd4lodmGuaX7nJIV5eHKnc4Pl[C=>	NGXrW3AyQTB{Mk[3OS=>
HCT116	MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{XNeFczcA>?	M4r6cmROW09?	MlHhTWM2OD1yLkOxJO69VQ>?	M4G1RlE6ODh2Mkm0
HeLa	M{D3[mtqdmG\|ZTDBd5NigQ>?	NEfEbnczKM7:TR?=	NYj1c2c1OzBibXnu	NUPySmtbTE2VTx?=	M{DFcWlvcGmkaYTpc44hd2ZiSFTBR\|IhcW5iaIXtZY4hUGWOYTDj[YxteyC5aYToJGlEPTBib3[gNE4yKM7:TR?=	NUXzU3hFOTlyOESyPVQ>
IGROV1	NWLtNYx6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYfiRpFEPzJiaB?=	NIf1b4lFVVOR	M{G4OmlEPTB;Mj6yJO69VQ>?	NU\rZ4N[OTlyOESyPVQ>
IGROV1	NW\HUXdvU2mwYYPlJGF{e2G7	MonmOUDPxE1?	NXnEcYhtOjRiaB?=	NV;xZo1xTE2VTx?=	NWrGcJBzUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IIC1N{Bi[2W2eXzheIlwdg>?	NFPkWJQyQTB6NEK5OC=>
IGROV1	MYLLbY5ie2ViQYPzZZk>	NFzFdG0yOCEQvF2=	MXq0JIg>	MWXEUXNQ	MkXOTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGirc4TvcoUuUDRiYXPleJlt[XSrb36=	MVWxPVA5PDJ7NB?=
IGROV1	NUDybHQ3U2mwYYPlJGF{e2G7	M1nVO\|ExKM7:TR?=	M4\oSFQhcA>?	M1rFR2ROW09?	MVXJcohq[mm2aX;uJI9nKEiGQVO2JIF{e2W\|c3XkJIF{KGGucHjhMZR2[nWuaX6gZYNmfHmuYYTpc44>	M3PmXVE6ODh2Mkm0
T24	M{TyemtqdmG\|ZTDBd5NigQ>?		MnPhN{Bp		NHuxV4NKdmS3Y4Tpc44hd2ZiaHnzeI9v\SCKMzDhZ4V1gWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6xNkDPxE1?	NF;4OFMyQTB6NEO5OS=>
T24	MUTLbY5ie2ViQYPzZZk>		MXuzJIg>		MUDJcoR2[3Srb36gc4Yh[WyyaHGgeJVjfWyrbjDhZ4V1gWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6yOUDPxE1?	NY[4TndKOTlyOESzPVU>
HeLa	MUjLbY5ie2ViQYPzZZk>		MkTjNVUhdWmw	MXLEUXNQ	M{ThOGlvcGmkaYTpc44hd2ZiSFTBR\|Yh\nKxbTDueYNt\WG{IHX4eJJi[3Rid3n0bEBKSzVyIH;mJFAvODh3NTFOwG0>	M1XzZ\|E6ODl\|OEi0
HeLa	Ml\lT4lv[XOnIFHzd4F6		M{DnSlE2KG2rbh?=	NYfmN21lTE2VTx?=	NIjEeplKdmirYnn0bY9vKG:oIFjERWM5KG[{b32gcpVkdGWjcjDlfJRz[WO2IIfpeIghUUN3MDDv[kAyNjh4IN88US=>	MonjNVkxQTN6OES=
NCI-H69	Ml3ZR5l1d3SxeHnjJGF{e2G7		NVXlNIdjPzJiaB?=	NGniZlZFVVOR	NHrGO4tKSzVyPUKuNFYh\|ryP	MlSwNVkxQTN6OES=
SKMES1	NUn1bYQ2S3m2b4TvfIlkKEG\|c3H5		MmrXO\|IhcA>?	NY\CVWg3TE2VTx?=	M3TFZ2lEPTB;Mj60NkDPxE1?	M{XhNlE6ODl\|OEi0
S2	MnXET4lv[XOnIFHzd4F6	M3PPXlAvOS1zMDFOwG0>	NH31TIgyKGh?		MWLJcohq[mm2aX;uJI9nKFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDISGFEOSCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFAvODV7IN88US=>	NVvQe\|ZiOTl\|MUe0OVA>
SHSY5Y	MYTLbY5ie2ViQYPzZZk>	MYSxNEDPxE1?	MlTyOFghcA>?	NUDHdXN7TE2VTx?=	M2O3OGlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD61JO69VQ>?	M4rKRVE6OzR2MUe1
SHSY5Y	M2C2PGN6fG:2b4jpZ{BCe3OjeR?=	NXW3cGxEOTBizszN	MmHGOFghcA>?	MYDEUXNQ	NIPXbG1KSzVyPUKg{txO	MX6xPVM1PDF5NR?=
DMS114	MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2ewOFQ5KGh?		NITNdHNIUTVyPUKuPUDPxE1?	M1fX[lE6PDF7MkC1
HBC5	Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV7qRohDPDhiaB?=		NWXxV49CT0l3ME2xO{DPxE1?	NFj1VYsyQTRzOUKwOS=>
SNB78	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NG\YWnc1QCCq		M2qwRWdKPTB;MU[g{txO	MWWxPVQyQTJyNR?=
HeLa	NV3EZZV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUm3NkBp	M3m5N2ROW09?	MlLVTWM2OD1yLkS2JO69VQ>?	MY[xPVQ1OTh2Nh?=
BHK	NI\GWZVMcW6jc3WgRZN{[Xl?	NG\w[os2KM7:TR?=	NFrDbYUzPCCq	M{jv[mROW09?	MXzJcohq[mm2aX;uJI9nKEiGQVO3JIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwcIF{dWFibXXtZpJidmViRnTlcJRiPTB6IFPGWHIheHKxdHXpci=>	MUixPVk3Pjd6OR?=
CFBE41o-	Mo\pT4lv[XOnIFHzd4F6	NU\Qfo1iPSEQvF2=	MlfFPEBp	NF\1TVlFVVOR	NXLWNXBjUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHj5dIVz[WOndInsZZRqd25ib3[gbIl{fG:wZTDINy=>	MoTMNVk6PjZ5OEm=
CFBE41o-	MnjlT4lv[XOnIFHzd4F6	NHHtOWw2KM7:TR?=	MWq0JIg>	MofJSG1UVw>?	NUPvfJl[UW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJI12fGGwdDDG[IVtfGF3MEigR2ZVWiCycn;0[YlvKGyndnXs	M1jvXlE6QTZ4N{i5
CFBE41o-	MlW1T4lv[XOnIFHzd4F6	M3\WTFEh\|ryP	NXH0TmE{OSCq	NFvPOHlFVVOR	MVrJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iQ1\UVkBxem:2ZXnuJIxmfmWu	NWTUdlNEOTl7Nk[3PFk>
Primary bronchial epithelial cell	MVLLbY5ie2ViQYPzZZk>	M2S0UVEh\|ryP	MlPNNlQhcA>?	MkPoSG1UVw>?	NUnS[5N2UW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhdXW2YX70JGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5iYYDpZ4FtKHO3cn\hZ4UhdG:lYXzpfoF1cW:w	MYKxPVk3Pjd6OR?=
CFBE41o-	M2HweGtqdmG\|ZTDBd5NigQ>?	NUT4[HplOSEQvF2=	M2nxUVUh\GG7cx?=	NV7jS2dLTE2VTx?=	MUPJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIP0ZYJqdGm8YYTpc44hd2ZiRnTlcJRiPTB6IFPGWHIheHKxdHXpci=>	MX6xPVk3Pjd6OR?=
CFBE41o-	M4nVTGtqdmG\|ZTDBd5NigQ>?	NYK2WIZIOSEQvF2=	NVPudpN3OjRiaB?=	M2W4dmROW09?	NHvLUIFKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5idILh[oZq[2urbne=	NHnydXgyQTl4Nke4PS=>
CFBE41o-	M4nId2tqdmG\|ZTDBd5NigQ>?	M2jDR\|Uh\|ryP	MlPQNlQhcA>?	NF;2R2lFVVOR	MnXKTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDyZZRmKG:oIH3heJVz[XSrb36gc4YhS0[WUjDwdo91\WmwIITvJIl1eyCpbInjc4Zwem1?	M1fzO\|E6QTZ4N{i5
CFBE41o-	NIPOcYVMcW6jc3WgRZN{[Xl?	Mny2OUDPxE1?	NXzNXnF3OjRiaB?=	NFfkSGRFVVOR	NF;ZVmxKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJN1[WKrbHn0fUBw\iCIZHXseIE2ODhiQ1\UVkBxem:2ZXnu	NF\DSVYyQTl4Nke4PS=>
CFBE41o-	NGHycpNMcW6jc3WgRZN{[Xl?	NWH2ZWJDPSEQvF2=	MkD5NlQhcA>?	MnXMSG1UVw>?	NYT2XINPUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDjc5Jz\WO2aX;uJI9nKG23dHHueEBH\GWudHG1NFghS0[WUjD0doFn\mmla3nu[{B1dyClZXzsJJN2em[jY3WgZZMh\2y7Y3;mc5Ju	M4C5eFE6QTZ4N{i5
Primary bronchial epithelial cell	NHLaZlBMcW6jc3WgRZN{[Xl?	MYS1JO69VQ>?	M1G2fVI1KGh?	NY\xT5pMTE2VTx?=	M3jISWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4h[XCrY3HsJJN2em[jY3WgcI9k[WyrenH0bY9v	Mmf6NVk6PjZ5OEm=
Primary bronchial epithelial cell	MnT3T4lv[XOnIFHzd4F6	M{\tb\|Eh\|ryP	MU[5OkBp	M{jBRWROW09?	NEft[2ZKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJNpd3K2IHPpdoN2cXRiY4XydoVvfHN?	NWfsXmJDOTl7Nk[3PFk>
BxPC3	NEjRT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFXTXoc4OiCq		NVLVboE5UUN3ME2yMlch\|ryP	Mn\iNlAyPDN5N{i=
CAL27	M2HX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXT2SlNWPzJiaB?=		NWXVO5VLUUN3ME2zMlczKM7:TR?=	MnTCNlAyPDN5N{i=
Capan1	MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVrVNXhHPzJiaB?=		MkjOTWM2OD15LkOg{txO	NEXGTmwzODF2M{e3PC=>
HCC827	NUPyZ49CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEn0VHc4OiCq		M{TsPGlEPTB;MT64JO69VQ>?	NFi2[G4zODF2M{e3PC=>
LNCAP	NGC5WXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4qzcVczKGh?		Ml36TWM2OD1yLkW4JO69VQ>?	MlTlNlAyPDN5N{i=
NCI-H2122	NFPQcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVO3NkBp		NWmyUFhHUUN3ME23MlUh\|ryP	M4W2OFIxOTR\|N{e4
NCI-H358	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYPQN4xPPzJiaB?=		MWjJR\|UxRTJwNTFOwG0>	MoLxNlAyPDN5N{i=
SCC15	NYXHe2I6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFzkPIw4OiCq		NIG2UlFKSzVyPUKuOFkh\|ryP	NWnLbmw{OjBzNEO3O\|g>
SCC25	M4[4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml7hO\|IhcA>?		MmDBTWM2OD1zLkmzJO69VQ>?	MnvPNlAyPDN5N{i=
SKHEP1	M2e5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnjmO\|IhcA>?		M4LafWlEPTB;Mz60OkDPxE1?	NVG1ZXN5OjBzNEO3O\|g>
BJ	NWnzXXVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vyelExOCEQvF2=	NXjvNlh2PDhiaB?=	M1TkRWROW09?	Mn3TS5Jwf3SqIHnubIljcXSrb36gZZQhOC5yNTD0c{AyODBidV2=	MWeyNFE1Ozh2MB?=
MUF	M4rBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnOZ5gyODBizszN	NWG3VWw2PDhiaB?=	M3\COWROW09?	M2HXeGdzd3e2aDDpcohq[mm2aX;uJIF1KDBwMEWgeI8hOTByIIXN	NXXnRoNVOjBzNEO4OFA>
Caco-2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXJO5gyODBizszN	M3nMZlQ5cA>?	MWTEUXNQ	NXzFO\|d3UUN3ME24MlEh\|ryP	MWSyNFE1Ozh2MB?=
Caco-2	MYXLbY5ie2ViQYPzZZk>	MnX4OUDPxE1?	Mn2wOEBp	MVLEUXNQ	M3;0d2lv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJIhqe3SxbnWgZYNmfHmuYYTpc44hUUN3MDDv[kAxNjB\|NzFOwG0>	MVSyNFE1Ozh2MB?=
Caco-2	NF2xO41McW6jc3WgRZN{[Xl?	M4izXFAvOzF4IH7NJJRwKDNzLk[g{txO	NFzYdJk1KGh?	NUXDS4JOTE2VTx?=	Ml7JSZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUNzIIfpeIghUUN3MDDv[kAxNjFzOTFOwG0>	M4r1VFIxOTR\|OESw
Caco-2	NVPUd49vU2mwYYPlJGF{e2G7	M17YTVAvOzF4IH7NJJRwKDNzLk[g{txO	M3fUU\|QhcA>?	NUK4R4oyTE2VTx?=	MUHFfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzNid3n0bEBKSzVyIH;mJFAvOTR5IN88US=>	MUWyNFE1Ozh2MB?=
Caco-2	MUXLbY5ie2ViQYPzZZk>	NFPVc3M3NjN{IH7NJJRwKDZ\|MjFOwG0>	MXq0JIg>	NVHhXmJuTE2VTx?=	MV\FfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzVid3n0bEBKSzVyIH;mJFEzNjZizszN	MYCyNFE1Ozh2MB?=
Caco-2	NYflV5NwU2mwYYPlJGF{e2G7	NH21UWY3NjN{IH7NJJRwKDZ\|MjFOwG0>	NVf0NI1kPCCq	M4TKRmROW09?	Mkf5SZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN5IIfpeIghUUN3MDDv[kA1OSEQvF2=	NUPRdXZzOjBzNEO4OFA>
Caco-2	NWrCR2pzU2mwYYPlJGF{e2G7	MV:wMlMyPiCwTTD0c{A{OS54IN88US=>	M3L5ZlQhcA>?	MlzDSG1UVw>?	MX7FfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzZ?	NVLGbXA6OjBzNEO4OFA>
HepG2	NU\zcI14U2mwYYPlJGF{e2G7	MWq1JO69VQ>?	M3f0WVZp	M2DnbmROW09?	M{PodGlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJIhqe3SxbnWgZYNmfHmuYYTpc44>	NFvaOlczODF2M{i0NC=>
HepG2	M4\rbWtqdmG\|ZTDBd5NigQ>?	M4XlOlUh\|ryP	NIPzVXc3cA>?	NWXKRVkzTE2VTx?=	MnPiTY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgbIl{fG:wZTDofZBmemGlZYT5cIF1cW:w	M2jyPVIxOTR\|OESw
HepG2	M2\PSWtqdmG\|ZTDBd5NigQ>?	M2LSdFUh\|ryP	NWDX[XBKPmh?	NVnSd3BDTE2VTx?=	MlHWTY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgZYxxcGFvdIXieYxqdiCjY3X0fYxifGmxbh?=	MWeyNFE1Ozh2MB?=
HepG2	MYTLbY5ie2ViQYPzZZk>	M2fsUlUh\|ryP	MkTKOog>	MVrEUXNQ	M1\ZeGlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJGg{N0h2IHjpd5RwdmViYXPleJlt[XSrb36=	MkjRNlAyPDN6NEC=
COLO205	NWrlPWFLU2mwYYPlJGF{e2G7	MVuxNEDPxE1?	NH3rNZMzPCCq	NHrrUFdFVVOR	MX3Jcohq[mm2aX;uJI9nKEiGQVOxJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDobZN1d26nIFizJIFk\XS7bHH0bY9vKHerdHigTWM2OCCxZjCyMlIh\|ryP	M3jJeVIxPDVzM{e4
SCC4	NX:3O3pMU2mwYYPlJGF{e2G7	NYHqSVN{OSEQvF2=	MnLwNlRp		NGe0RXZKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6geJVjfWyrbjDhZ4V1gWyjdHnvci=>	NEPGT5IzODR3MkKyOS=>
SCC4	NILhRmRMcW6jc3WgRZN{[Xl?	NWLudFNbOSEQvF2=	NX;qdmtQOjSq		M2\h[2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIHHj[ZR6dGG2aX;u	MnvnNlA1PTJ{MkW=
SCC4	MVvGeY5kfGmxbjDBd5NigQ>?	MUixJO69VQ>?	M3;0ZlUhdWmw		M3PVeWFod26rc4SgZYN1cX[rdImgZZQhXkSUIHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCFWWCyOEBo\W6nIHX4dJJme3Orb36=	NHT0RmgzODR3MkKyOS=>
NB4	NWLoRVlnTnWwY4Tpc44hSXO\|YYm=	Mn3BOUDPxE1?	MXiyOEBp	Mkj1SG1UVw>?	MYHD[YxtKGO7Y3zlJIFzemW\|dDDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjY3P1cZVt[XSrb36gZZQheHKnLVexJJBp[XOn	MnnzNlA1QTF2NEC=
NB4	NVrNeYNXU2mwYYPlJGF{e2G7	MUK1JO69VQ>?	MYiyOEBp	MmjXSG1UVw>?	M3jp[mlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4V1gWyjdHWgeJVjfWyrbjDs[ZZmdA>?	NVe1cmxWOjB2OUG0OFA>
NB4	NIniSXhHfW6ldHnvckBCe3OjeR?=	NV;CNmI4PSEQvF2=	Ml[0NlQhcA>?	NHP2U2RFVVOR	MVzJcoR2[3Srb36gc4YheDJzV1HGNU9EUVBzIHX4dJJme3Orb36=	MYKyNFQ6OTR2MB?=
NB4	MU\LbY5ie2ViQYPzZZk>	MmC2OUDPxE1?	MoPNNlQhcA>?	NEnr[lRFVVOR	NGnjZ4ZKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{Bi[2W2eXzheIlwdg>?	NEf3O3UzODR7MUS0NC=>
NUGC3	MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvMOGJjT0l3ME2yMlk1KM7:TR?=	MXGyNFg2ODl5MR?=
A549	Mn7JSpVv[3Srb36gRZN{[Xl?	NGnYdos2KM7:TR?=	Ml7JN{Bp	M1q3UmROW09?	M4TFNGlv\HWldHnvckBw\iCjdYTvdIhi\3liaX6gbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCOQ{PJTS=>	NV7WU5prOjB6NUWyNFg>
HUT78	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3PlOVczKGh?	NFmwN\|NFVVOR	NFzGU2ZIUTVyPUCuN{DPxE1?	MmnXNlA5QDR{MEi=
U937	NUH6NZhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4W0d\|czKGh?	M4XhW2ROW09?	NYjjXFBET0l3ME2wMlM6KM7:TR?=	M{XsclIxQDh2MkC4
A431	MlXDR5l1d3SxeHnjJGF{e2G7		M3\Jb\|czKGh?		M4Gwe2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMhd3[ncnX4dJJme3OrbnegSWdHWiC5aYToJGlEPTBib3[gOE4zKM7:TR?=	NEnzZXMzOTB6ME[yPS=>
A549	NXjZbFlRS3m2b4TvfIlkKEG\|c3H5		MWO3NkBp		M4XRfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMhd3[ncnX4dJJme3OrbnegTGRCSyC5aYToJGlEPTBib3[gNU45KM7:TR?=	MlTkNlExQDB4Mkm=
CAL27	MmqzR5l1d3SxeHnjJGF{e2G7		M1fDV\|czKGh?		NV30WGpJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0GOMkegZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjD3bZRpKEmFNUCgc4YhOy5{IN88US=>	M2fn[lIyODhyNkK5
HeLa	NGq3V5BEgXSxdH;4bYMhSXO\|YYm=		MVO3NkBp		NIGxZ2ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGhFSUNid3n0bEBKSzVyIH;mJFEvPSEQvF2=	NFj0OoMzOTB6ME[yPS=>
Sf21	MXfLbY5ie2ViQYPzZZk>		NXPpcY1{OyCq		MWLJcohq[mm2aX;uJI9nKE[uYXegeIFo\2WmIHj1cYFvKHKnY3;tZolv[W62IFjERWM5KGW6cILld5Nm\CC5aYToJGlEPTBib3[gNU4zKM7:TR?=	M{jmfFIyODhyNkK5
SKBR3	MYHDfZRwfG:6aXOgRZN{[Xl?		MnXPO\|IhcA>?		NIDo[W5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0KUMzDj[YxteyCxdnXy[ZhxemW\|c3nu[{BJTVJ{IIfpeIghUUN3MDDv[kAzNjZizszN	M4rIVFIyODhyNkK5
SKOV3	Mle4R5l1d3SxeHnjJGF{e2G7		MoW1O\|IhcA>?		MmnoR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMhd3[ncnX4dJJme3OrbnegTGVTOiC5aYToJGlEPTBib3[gNk4zKM7:TR?=	NVjwbItiOjFyOEC2Nlk>
COR-L23	M3nocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jleVExKM7:TR?=	MUS3NkBp	M2H3OWROW09?	NWf2[HpET0l3ME2xMlEh\|ryP	MVGyNVA5ODZ2Nx?=
DU145	MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHj2e2QyOCEQvF2=	M3XQSlczKGh?	MX7EUXNQ	MU\HTVUxRTFwMEWg{txO	MUmyNVA5ODZ2Nx?=
LoVo	M2G1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPadYcyOCEQvF2=	M1jQ[VczKGh?	M3LsUWROW09?	NFrLfXhIUTVyPUGuO{DPxE1?	MX2yNVA5ODZ2Nx?=
MCR5-SV2	MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXThZYVOOTBizszN	M3njWVczKGh?	NFv4VJBFVVOR	Mn6xS2k2OD1{LkGg{txO	NGHjO4IzOTB6ME[0Oy=>
HCT116	NUfXfmdHU2mwYYPlJGF{e2G7	M{L2eFMxKM7:TR?=	MYmzNEBp	Ml[zSG1UVw>?	NUnYdIV7UW6qaXLpeIlwdiCxZjDISGFEPiCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4Yh[WyyaHGteJVjfWyrbjDhZ4V1gWyjdHnvci=>	NGnPcGszOTB6ME[0Oy=>
HCT116	NYPCdXhCU2mwYYPlJGF{e2G7	NUnnOmxsOzBizszN	Mmn4N\|AhcA>?	MUnEUXNQ	MYXJcohq[mm2aX;uJI9nKEiGQVOxJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDobZN1d26nIFizT\|kh[WOndInsZZRqd25?	MYOyNVA5ODZ2Nx?=
U937	M2PSW2tqdmG\|ZTDBd5NigQ>?	NYTI[ZJwPSEQvF2=	NV\nTnNLOjRiaB?=	MlTkSG1UVw>?	NYH3[XR6UW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiS{m=	NGXkSIczOTJ7MkS5Ni=>
U937	NXLITJFXU2mwYYPlJGF{e2G7	NXPBd2plPSEQvF2=	MkC5NlQhcA>?	MXfEUXNQ	NWPtNlF1UW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiS{G4	Mk\pNlEzQTJ2OUK=
U937	M1zIVWtqdmG\|ZTDBd5NigQ>?	MWK1JO69VQ>?	M{XhNFI1KGh?	M3rnPGROW09?	MX3Jcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO\|ZYPz[YQh[XNiaX7jdoVie2Vib3[gdIFvNWGlZYT5cIF1\WRiaHnzeI9v\SCKNDDs[ZZmdA>?	NUnMd\|J7OjF{OUK0PVI>
U937	NEjwVGlMcW6jc3WgRZN{[Xl?	M{T5flUh\|ryP	NFXGc4cyPSCvaX6=	MVTEUXNQ	NIHKXoVKdmirYnn0bY9vKG:oIHjpd5RwdmViYXPleJltfHKjboPm[ZJie2ViYYPz[ZN{\WRiYYOgbY5kemWjc3Wgc4YhcGm\|dH;u[UBJOyCjY3X0fYxifGmxbjDs[ZZmdA>?	NXS4[XdZOjF{OUK0PVI>
A2780	NILMZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFLOV4Q6PiCq	NFPIc2RFVVOR	NF;Cc5RKSzVyPUGuOlIh\|ryP	M{TOTFIyPjN2NEOw
COLO205	M1znN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1q1clk3KGh?	MYTEUXNQ	NHK0fVJKSzVyPUKuNVIh\|ryP	NXrmWIJSOjF4M{S0N\|A>
Hep3B	MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUn1N2VyPDhiaB?=	NIfwXnVFVVOR	MmT5S2k2OD1zLkKxJO69VQ>?	NX\DTGI4OjF5MUKxOFY>
GM11272	MmfnSpVv[3Srb36gRZN{[Xl?	NXfvdJVvOTByIH7N	MVS3NkBp	MXTEUXNQ	MlXQVoVi[3SrdnH0bY9vKG:oIF3lR5AzKG23dHHueEBmgHC{ZYPzbY9vKGG2IEGwJJRwKDFyMDDuUS=>	NWXP[o1OOjF6NEC3NVY>
CFBE41o	M4PnVGtqdmG\|ZTDBd5NigQ>?	MUC1JO69VQ>?		M4fOemROW09?	M4rWbmRwf25icnXneYxifGmxbjDv[kBJTEGFNzDheEAxNjJidH:gOUB2VQ>?	MlPwNlE6QDR7NUi=
CFBE41o	NUHXN5ZlTnWwY4Tpc44hSXO\|YYm=	MWKxJO69VQ>?	MoXaNlQhcA>?	NVzIOGhNTE2VTx?=	NVj6eVdGWmW\|dH;yZZRqd25ib3[gR2ZVWiCmZXz0ZWY2ODhibYX0ZY51KHS{YX\mbYNscW6pIITvJINmdGxic4Xy[oFk\SCjczDncJlkd2[xcn3z	M3jvXVIyQTh2OUW4
DU145	M3m3c2tqdmG\|ZTDBd5NigQ>?	MnjqNk42KM7:TR?=	NWWxN4ZqOjRiaB?=	MVnEUXNQ	M1HXT2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyC3cILl[5Vt[XSrb36gc4YheDJzd3HmNUBxem:2ZXnuJIV5eHKnc4Ppc44>	MX6yNlI3ODF4Nh?=
DU145	MnHjT4lv[XOnIFHzd4F6	M1SzdVUh\|ryP	MkPtNlQhcA>?	NF:1dG5FVVOR	MkTkTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGirc4TvcoUhUDRiYXPleJlt[XSrb36=	MYOyNlI3ODF4Nh?=
DU145	MXnLbY5ie2ViQYPzZZk>	M4DENlUh\|ryP	MmDRNlQhcA>?	MWjEUXNQ	NGTYdGtKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaHnzeI9v\SCKMzDofZBmemGlZYT5cIF1cW:w	M{ThN\|IzOjZyMU[2
786-0	M4K5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXq2MlIh\|ryP	M33TXVczKGh?	MofHSG1UVw>?	M1nuT2dKPTB;Mz6yJO69VQ>?	NXTE[VRmOjJ2M{W2Olk>
A498	NEfpRlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWi2MlIh\|ryP	NWWzT5lSPzJiaB?=	MmDlSG1UVw>?	NWrKcGtjT0l3ME2xMlYh\|ryP	MV:yNlQ{PTZ4OR?=
A549/ATCC	NHfyOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HvTlYvOiEQvF2=	MVK3NkBp	M2TYemROW09?	NHnUVWhIUTVyPUGuOkDPxE1?	M{DWV\|IzPDN3Nk[5
ACHN	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXm2MlIh\|ryP	MUm3NkBp	NH\4R2JFVVOR	M4fnW2dKPTB;MT6zJO69VQ>?	M4njc\|IzPDN3Nk[5
BT549	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHH4UWI3NjJizszN	MUe3NkBp	MWLEUXNQ	NYXMWmNrT0l3ME2xMlMh\|ryP	MmrINlI1OzV4Nkm=
EKVX	NXr5XItHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnv5Ok4zKM7:TR?=	M2LWRVczKGh?	NGjL[IZFVVOR	MWjHTVUxRTFwMzFOwG0>	MWeyNlQ{PTZ4OR?=
HCT15	NFPhZ3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVm2MlIh\|ryP	NWHrZXFvPzJiaB?=	MULEUXNQ	Mn70S2k2OD1{LkWg{txO	MYSyNlQ{PTZ4OR?=
HOP92	NI\vXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fnZ\|YvOiEQvF2=	NHHtcWs4OiCq	MX3EUXNQ	M1\DXGdKPTB;NDFOwG0>	MlG5NlI1OzV4Nkm=
IGROV1	M3PPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXjOXk3NjJizszN	MmrmO\|IhcA>?	M13yb2ROW09?	MXvHTVUxRTFwMzFOwG0>	NYLNZ2hxOjJ2M{W2Olk>
LOXIMVI	M{PxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jiUVYvOiEQvF2=	M1nnbVczKGh?	NXHuenFCTE2VTx?=	M4Sw[WdKPTB;MTFOwG0>	Mn\oNlI1OzV4Nkm=
M14	NUjlSXA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWK2MlIh\|ryP	MX[3NkBp	M2Ly[2ROW09?	MljNS2k2OD1zLkOg{txO	NXizV\|NIOjJ2M{W2Olk>
MALME-3M	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XLclYvOiEQvF2=	Mn;6O\|IhcA>?	MlHRSG1UVw>?	NVnhVHpmT0l3ME2wMlMzKM7:TR?=	NUC3dZhjOjJ2M{W2Olk>
MCF10A	Mn;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfhSJg3NjJizszN	Ml71OFghcA>?	NX7wOW1KTE2VTx?=	MnjjS2k2OD17Lk[g{txO	NFn1VFIzOjR\|NU[2PS=>
MDA-MB-435	NET2TZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;vbZc3NjJizszN	NInvdIk4OiCq	M{DQVGROW09?	Mlf6S2k2OD1yLkWg{txO	MX[yNlQ{PTZ4OR?=
MDA-MB-468	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rlWVYvOiEQvF2=	M2DTWFczKGh?	MVHEUXNQ	NXPoSGpJT0l3ME2wMlY{KM7:TR?=	NIn4WngzOjR\|NU[2PS=>
MOLT4	MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nvUlYvOiEQvF2=	MVK3NkBp	NWfJbpJnTE2VTx?=	MoD1S2k2OD1yLkSg{txO	NWfScHZtOjJ2M{W2Olk>
NCI-ADR-RES	M1PH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NED1Zmw3NjJizszN	NVjWT4ZrPzJiaB?=	NHjDWoFFVVOR	NIT1UlRIUTVyPUCuNVYh\|ryP	NVjGeGN4OjJ2M{W2Olk>
NCI-H23	NWnKeIU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\3N4Q{Pi5{IN88US=>	MlS0O\|IhcA>?	Moe1SG1UVw>?	NI\PPIVIUTVyPUGg{txO	MkT5NlI1OzV4Nkm=
NCI-H322M	M1rmRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV:2MlIh\|ryP	NGPab3M4OiCq	M1LVOmROW09?	M1X6W2dKPTB;MD63PUDPxE1?	M1y1S\|IzPDN3Nk[5
NCI-H460	MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3P3VFYvOiEQvF2=	M1iwSlczKGh?	MkKwSG1UVw>?	NY\hcJhRT0l3ME2wMlc6KM7:TR?=	MUSyNlQ{PTZ4OR?=
NCI-H522	NVvvbpZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVu2MlIh\|ryP	NYnYSnk5PzJiaB?=	NXXuSHI2TE2VTx?=	Ml;ES2k2OD1yLkWg{txO	MX[yNlQ{PTZ4OR?=
OVCAR3	NEPO[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2noPFYvOiEQvF2=	MWm3NkBp	MVfEUXNQ	MlfHS2k2OD1zLkOg{txO	M1vqS\|IzPDN3Nk[5
OVCAR4	M4H4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjnS5J3Pi5{IN88US=>	NGXlUm84OiCq	M3\Oe2ROW09?	NFvJSYxIUTVyPUSg{txO	M4fZNFIzPDN3Nk[5
OVCAR5	M3G0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXHVHpmPi5{IN88US=>	MXK3NkBp	MUfEUXNQ	Mn:yS2k2OD1yLke5JO69VQ>?	MWCyNlQ{PTZ4OR?=
OVCAR8	M4r0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVr3b4pNPi5{IN88US=>	M3zZbVczKGh?	NVe1SpdxTE2VTx?=	MXHHTVUxRTBwNTFOwG0>	M33PTlIzPDN3Nk[5
RXF393	NV\D[JNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17PN\|YvOiEQvF2=	NWTiSmhuPzJiaB?=	M3zTWWROW09?	NH\FeYFIUTVyPUGuN{DPxE1?	MnjnNlI1OzV4Nkm=
SF268	MmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWm2MlIh\|ryP	MVS3NkBp	NEjEUWxFVVOR	MXnHTVUxRTFwNjFOwG0>	MW[yNlQ{PTZ4OR?=
SF295	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\rcHA3NjJizszN	M4LtfVczKGh?	MmHtSG1UVw>?	M3\ZN2dKPTB;MT62JO69VQ>?	NYj3dVdSOjJ2M{W2Olk>
SF539	M3rJNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvlOk4zKM7:TR?=	NFP2dGg4OiCq	M4r2fmROW09?	MojPS2k2OD1{IN88US=>	M4\0eFIzPDN3Nk[5
SK-MEL-2	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVG4fYdIPi5{IN88US=>	MV[3NkBp	MmiwSG1UVw>?	NIjhc5dIUTVyPUGuN{DPxE1?	NVjzTFd1OjJ2M{W2Olk>
SK-MEL-28	M1zvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYW2MlIh\|ryP	MWe3NkBp	NFvMU5hFVVOR	M{XOVmdKPTB;MTFOwG0>	NYO2Z3RYOjJ2M{W2Olk>
SK-MEL-5	MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPBOk4zKM7:TR?=	NVyzcYt3PzJiaB?=	M2H0[mROW09?	NX;6Xo5[T0l3ME2wMlY{KM7:TR?=	MorXNlI1OzV4Nkm=
SKOV3	NUnnNY1tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV62MlIh\|ryP	NWP6e4VIPzJiaB?=	MW\EUXNQ	M1:3NWdKPTB;MTFOwG0>	NWjrTWh4OjJ2M{W2Olk>
SN12C	M2Lqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFL1WFc3NjJizszN	MYq3NkBp	MnnUSG1UVw>?	NF36XllIUTVyPUKg{txO	NFvEcXYzOjR\|NU[2PS=>
SNB19	NHzPUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\EWlYvOiEQvF2=	NFrPeYI4OiCq	NV\wZ4VtTE2VTx?=	MoLTS2k2OD1yLk[zJO69VQ>?	MkLjNlI1OzV4Nkm=
SNB75	NXLuWZhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVe2MlIh\|ryP	M1jHbFczKGh?	NVvNUm1lTE2VTx?=	NWXKOYRXT0l3ME2wMlc6KM7:TR?=	NHq4bGozOjR\|NU[2PS=>
SR	NFXndIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TDNFYvOiEQvF2=	MUm3NkBp	NHTJdGFFVVOR	NUjhR\|FPT0l3ME2wMlQh\|ryP	M{KxeVIzPDN3Nk[5
T47D	MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUi2MlIh\|ryP	NHnzN5g4OiCq	M3ThZmROW09?	MXXHTVUxRTBwNTFOwG0>	M3PGfVIzPDN3Nk[5
TK10	M37TbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV62MlIh\|ryP	NIPXWIU4OiCq	MULEUXNQ	Mlu1S2k2OD1yLk[zJO69VQ>?	MUGyNlQ{PTZ4OR?=
UACC257	NUD2[npTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7RUlk3NjJizszN	MVK3NkBp	MoHsSG1UVw>?	Mmr2S2k2OD1yLkWg{txO	NGfJU5kzOjR\|NU[2PS=>
UACC62	M1jwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DwTlYvOiEQvF2=	MVK3NkBp	Moq3SG1UVw>?	M1:5PWdKPTB;MD60JO69VQ>?	NV7FV2ZkOjJ2M{W2Olk>
UO31	MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2K4PVYvOiEQvF2=	MXy3NkBp	MYrEUXNQ	MoCxS2k2OD1yLkWg{txO	MonONlI1OzV4Nkm=
Hep3B	NIDYVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUC0PEBp	MlfySG1UVw>?	NXTWOYhGT0l3ME2wMlY6KM7:TR?=	MoXKNlI1Ozl6NkO=
BE(2)-C	MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXn5UnprPzJiaB?=	Mn7tSG1UVw>?	NEjqOXBKSzdyPUKg{txO	MX2yNlk{OjNzNh?=
Bel7402	NWjycm5IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWDZV3k1PzJiaB?=	MkTHSG1UVw>?	MmSyS2k6OD1zNzFOwG0>	NGTafXgzOzB4MUO3Oi=>
Bel7404	M2TiTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoD5O\|IhcA>?	Moj2SG1UVw>?	MVnHTVkxRTF6IN88US=>	MV:yN\|A3OTN5Nh?=
BGC823	NF\qdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmXnO\|IhcA>?	NVuwdWVkTE2VTx?=	M1nn[WdKQTB;Nz61JO69VQ>?	M3XVdlI{ODZzM{e2
MGC803	MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWe3NkBp	MoHYSG1UVw>?	M1PUOWdKQTB;MUCuPEDPxE1?	NYjIR49ZOjNyNkGzO\|Y>
SGC7901	NGLQTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH\KbXM4OiCq	Moi3SG1UVw>?	NHuxUZdIUTlyPUmuOEDPxE1?	MWiyN\|A3OTN5Nh?=
SKHEP1	NYPrZVhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn\CO\|IhcA>?	NWSxbYJ6TE2VTx?=	NUXXRZlNT0l7ME2xO{DPxE1?	NYK3NW5GOjNyNkGzO\|Y>
SMMC7721	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4\4PVczKGh?	NILVb2JFVVOR	NGHvenFIUTlyPUKwJO69VQ>?	MkG4NlMxPjF\|N{[=
NUGC3	MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDqWWcyOCEQvF2=			M1\HXWdKRTJwOUSg{txO	M3PWelI{OTZ\|M{Oy
A2780 CisR	MV7LbY5ie2ViQYPzZZk>		MmLJNVghcA>?		NEfIOVVKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOFQh\|ryP	M2q3OVI{OjV{NkCz
CAL27 sens	Ml;TT4lv[XOnIFHzd4F6		NVLkdYhTOThiaB?=		NVLi[oxJUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlM3KM7:TR?=	NF\0TJozOzJ3Mk[wNy=>
CAL27 CisR	MXTLbY5ie2ViQYPzZZk>		NGLZem0yQCCq		M2TM[GlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1?	NEPqeXIzOzJ3Mk[wNy=>
KYSE-510 CisR	Mlf1T4lv[XOnIFHzd4F6		MonmNVghcA>?		MYHJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNUmg{txO	MWCyN\|I2OjZyMx?=
KYSE-510 sens	NV7kfIg2U2mwYYPlJGF{e2G7		NUPpUoV3OThiaB?=		MXnJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNzFOwG0>	M1OzeVI{OjV{NkCz
MDA-MB-231 sens	NXz1[XdzU2mwYYPlJGF{e2G7		M4TRXFE5KGh?		NWnpUm5CUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlYyKM7:TR?=	M3[zXlI{OjV{NkCz
MDA-MB-231 CisR	NYXkTnBkU2mwYYPlJGF{e2G7		MmO0NVghcA>?		M3jVUmlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1?	Mln2NlMzPTJ4MEO=
ES2	M2LDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHy5[4U1QCCq	MoC2SG1UVw>?	M4rFNGlEPTB;MUKuO{DPxE1?	MV[yN\|Q6OzR2OR?=
MDA-MB-231	Mo[yT4lv[XOnIFHzd4F6	NGWzUZIyOCEQvF2=	M4TEXlMxKG2rbh?=	Ml;HSG1UVw>?	NWDXdZNIUW6qaXLpeIlwdiCxZjDISGFEOmF?	M{TkWVI{PDl\|NES5
MDA-MB-231	NVHlT3N2U2mwYYPlJGF{e2G7	MnnwNUDPxE1?	NYTPcYRSOjRiaB?=	NVn3ZYVwTE2VTx?=	M3y1ZmlvcGmkaYTpc44hd2ZiSFTBR\|Yh[XO\|ZYPz[YQh[XNiYXPleJlt[XSrb36gcIV3\Wy\|IH;mJJR2[nWuaX6=	NH\re4czOzR7M{S0PS=>
HS68	NXjqdVU4S3m2b4TvfIlkKEG\|c3H5	NIHIUGIyOCEQvF2=	NGLj[444OiCq	NELXTJhFVVOR	M4rJN2lEPTB;ND62JO69VQ>?	M4fTclI{PTdyNUSy
MEF	NVjKTXlYS3m2b4TvfIlkKEG\|c3H5	Mlq3NVAh\|ryP	NEHXb2E4OiCq	NG\xR\|ZFVVOR	NYnubXpxUUN3ME20MlQh\|ryP	M3;4bFI{PTdyNUSy
BGC823	MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3roPWROW09?	MXTHTVUxRTNwMEmg{txO	M17odFI{PjBzN{C2
High5	MnvrT4lv[XOnIFHzd4F6		NF;4fIczPCCq		NYHDTIRLUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEPiC5aYToJGlEPTBib3[gNE4xQSEQvF2=	M4HTZlI{PjB{NUKz
High5	MlfxT4lv[XOnIFHzd4F6		NF7Jc4wzPCCq		MYTJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOxJJdqfGhiSVO1NEBw\iByLkGyJO69VQ>?	NIrhRZYzOzZyMkWyNy=>
High5	Mlf2T4lv[XOnIFHzd4F6		MV6yOEBp		NY\QUohbUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEOyC5aYToJGlEPTBib3[gNE4yPyEQvF2=	MlHXNlM3ODJ3MkO=
A549	M1v6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NV\PNnU3TE2VTx?=	MX3JR\|UxRTFwMEe5JO69VQ>?	NIXWRYEzOzZ2NEKxNC=>
HCT116	M4rJVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFS5N2VFVVOR	NFrhV\|RKSzVyPUCuO\|U4KM7:TR?=	NWjWU4liOjN4NESyNVA>
K562	NWDKW492T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGLEdFdFVVOR	M{LscmlEPTB;MD62OFUh\|ryP	NX;G[FdJOjN4NESyNVA>
GBC-SD	NHjK[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TNeFUh\|ryP	NHj0Nok4OiCq	NVP2PJNKTE2VTx?=	Ml\UTWM2OD1zND64JO69VQ>?	NE\Kb2EzOzdyN{K2NC=>
HGC27	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2izbVUh\|ryP	NHXYTmk4OiCq	MU\EUXNQ	MlvwTWM2OD13LkSg{txO	MWeyN\|cxPzJ4MB?=
HL60	MmDtT4lv[XOnIFHzd4F6	NIPr[YE2KM7:TR?=	MmnRNlQhcA>?	M4rKdWROW09?	NVHHRo9ZUW6qaXLpeIlwdiCxZjDISGFE	MV2yN\|cxPzJ4MB?=
Vero	MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV:3NkBp	NYrP[FF2TE2VTx?=	MWLJR\|UxRTBwOTFOwG0>	NEPEeo0zOzd6NkS1Ni=>
NCI60	MVHDfZRwfG:6aXOgRZN{[Xl?		NHLDZWg1QCCq	MoTDSG1UVw>?	NE[3dYxIUT1yLkWzJO69VQ>?	MnnoNlQxOTV\|Mke=
SW620	NXLhR5BJS3m2b4TvfIlkKEG\|c3H5		NFPadY01QCCq	NI\hN2RFVVOR	NITDNHdIUT1yLkW0JO69VQ>?	NHLhVoMzPDBzNUOyOy=>
U251	M1n0TmN6fG:2b4jpZ{BCe3OjeR?=		MmDXOFghcA>?	MYnEUXNQ	Mn\ES2k:OS53MzFOwG0>	NXr0XZhMOjRyMUWzNlc>
KM12	MnjIR5l1d3SxeHnjJGF{e2G7		NGHnTII1QCCq	M{Tq[GROW09?	NInSWXlIUT1zLki4JO69VQ>?	M{i2b\|I1ODF3M{K3
Hs578T	NXLLfHc6S3m2b4TvfIlkKEG\|c3H5		MXq0PEBp	MWXEUXNQ	MmX0S2k:PC56MzFOwG0>	NVnafo5VOjRyMUWzNlc>
MDA-MB-231	NGL6Rm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3XCNFQ5KGh?		NYPMd\|l6UUN3ME2wMlE3KM7:TR?=	NHjEOpQzPDB7NUCxOi=>
MCF7	NGjLcIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFrqcHY1QCCq		M3S0bWdKRTBwNEWg{txO	M{jTUVI1OTF7NUW1
MDA-MB-435	NULVVVVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFL0XZA1QCCq		Mlm5S2k:OC56ODFOwG0>	M4HIO\|I1OTF7NUW1
AsPC1	MoXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlriN\|Ah\|ryP	MoHyOFghcA>?	Mn;hSG1UVw>?	MnzyTWM2OD1\|Lk[2JO69VQ>?	NGfBbnEzPDF6NUO3PC=>
Jurkat E6.1	NVPzcpFPU2mwYYPlJGF{e2G7		M{fLclIhcA>?	NXfScpdjTE2VTx?=	MU\Jcohq[mm2aX;uJI9nKEiGQVO0JJdqfGhiSVO1NEBw\iByLkC0JO69VQ>?	MXmyOFI3OTh4Mh?=
KG1	MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYX4VXdEPDhiaB?=		NHvQOW1KSzVyPUGuNVUh\|ryP	NF;qRlIzPDV{NUCwNy=>
HEL	M3jDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXW0WFBWPDhiaB?=	M1;BTGROW09?	M3G4PGlEPTB;MD60PUDPxE1?	NF;pN3czPDZ7NEC1OS=>
HSC3	MXTDfZRwfG:6aXOgRZN{[Xl?		MV:xNkBp	NUPlVFFyTE2VTx?=	M2LYNWlEPTB;MD63NUDPxE1?	NGDjT5EzPDd4NkW2NC=>
HT-29	M4XPSGN6fG:2b4jpZ{BCe3OjeR?=		M4HFZ\|EzKGh?	MlTrSG1UVw>?	M120c2lEPTB;MD63NkDPxE1?	MnX5NlQ4PjZ3NkC=
KB	NWPGOpNvS3m2b4TvfIlkKEG\|c3H5		MVexNkBp	M1HBS2ROW09?	NUm4dnl5UUN3ME2wMlc2KM7:TR?=	MkXFNlQ4PjZ3NkC=
H460	NWjTfJZkS3m2b4TvfIlkKEG\|c3H5		MXyxNkBp	M3zIWGROW09?	NU[3[m1oUUN3ME2wMlgzKM7:TR?=	NHnYfoYzPDd4NkW2NC=>
MONE1	M1X0RmN6fG:2b4jpZ{BCe3OjeR?=		Mo\NNVIhcA>?	MnHZSG1UVw>?	Ml;CTWM2OD1zLkG4JO69VQ>?	NXvmOYJ{OjR5Nk[1OlA>
MKN45	NX7CSZRTS3m2b4TvfIlkKEG\|c3H5		MVOxNkBp	NXTnRWtCTE2VTx?=	M4\4UmlEPTB;MT6yOUDPxE1?	Mm\1NlQ4PjZ3NkC=
TSGH	MkPGR5l1d3SxeHnjJGF{e2G7		MUGxNkBp	MkPtSG1UVw>?	MoD0TWM2OD1{LkC5JO69VQ>?	NVfmc2hjOjR5Nk[1OlA>
HL60	M2jB[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWO3NkBp	NWj3ZoNZTE2VTx?=	NUXYVmc2T0l3ME2wMlk{KM7:TR?=	NWrwOll3OjR7MEC1NFA>
HEK293	MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml\lO\|IhcA>?	NWLGUFZuTE2VTx?=	NF3DT4lIUTVyPUGzJO69VQ>?	M4jHfFI1QTByNUCw
Jurkat	NVvQPWtYS3m2b4TvfIlkKEG\|c3H5	M3HMTVExOCEQvF2=	MVi3NkBp		M3SwUGdKPTB;MD65JO69VQ>?	MViyOFkxODd2Mx?=
GM15850	M1fnZmtqdmG\|ZTDBd5NigQ>?	NYrNdHlEOi53IN88US=>	NWfxbWV3QTZiaB?=	NX;COVV7TE2VTx?=	NVW1eWVO\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDNibInzbY5mKDF2IHHj[ZR6dGG2aX;uJI9nKE[[TjDn[Y5m	MVqxOlkzOTN4Nx?=
GM15850	NEjWfJBMcW6jc3WgRZN{[Xl?	M1\nOlIvPSEQvF2=	MW[5OkBp	Mme1SG1UVw>?	Mnfl[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFUh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	NHvz[4wyPjl{MUO2Oy=>
GM15850	MmHmT4lv[XOnIFHzd4F6	MmTVNk42KM7:TR?=	NVztems2QTZiaB?=	MlzkSG1UVw>?	NUfNeHBC\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDRibInzbY5mKDF{IHHj[ZR6dGG2aX;uJI9nKE[[TjDn[Y5m	MojnNVY6OjF\|Nke=
GM15850	NVu5bo4xU2mwYYPlJGF{e2G7	NFPUdHAzNjVizszN	NHrKUWU6PiCq	MUPEUXNQ	NELT[nJld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJOyCueYPpcoUhQSCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=>	MVWxOlkzOTN4Nx?=
GM15850	MYDLbY5ie2ViQYPzZZk>	NY\lWVlkOi53IN88US=>	NHWyXHg6PiCq	NFO3TZRFVVOR	NVTpS\|dk\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDRibInzbY5mKDhiYXPleJlt[XSrb36gc4YhTliQIHflcoU>	NX3FN\|N3OTZ7MkGzOlc>
GM15850	M1vGc2tqdmG\|ZTDBd5NigQ>?	MUGyMlUh\|ryP	M2P5Slk3KGh?	MonYSG1UVw>?	NYfj[lIy\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDRibInzbY5mKDF4IHHj[ZR6dGG2aX;uJI9nKE[[TjDn[Y5m	MVOxOlkzOTN4Nx?=
GM15850	NXP6c\|U6TnWwY4Tpc44hSXO\|YYm=	MYq1JO69VQ>?	NWC5fGVZOTJiaB?=	NV72SYJpTE2VTx?=	NGHXPG9p[XNibn:g[YZn\WO2IH;uJGZZViCvUl7BJIV5eHKnc4Ppc44>	MYOxOlkzOTN4Nx?=
U937	M{m1[mtqdmG\|ZTDBd5NigQ>?	NH\vVVE2KM7:TR?=	MkPjNlQhcA>?	NWL3Z4ZUTE2VTx?=	NEfwRplp[XNibn:g[YZn\WO2IH;uJIFteGijIIT1ZpVtcW5iYXPleJlt[XSrb36=	MUGxO\|Q1Pzd3MB?=
U937	NWLLOmV1U2mwYYPlJGF{e2G7	NXjE[ZVGOSEQvF2=	MmTPNlQhcA>?	MnPuSG1UVw>?	NECzbotp[XNibn:g[YZn\WO2IH;uJIFteGijIIT1ZpVtcW5iYXPleJlt[XSrb36=	NV3GUlc5OTd2NEe3OVA>
PANC1	MlzTSpVv[3Srb36gRZN{[Xl?	M3rMflEh\|ryP	NX3TbFJnOjRiaB?=		NX\lTZB7\G:nczDuc5QhcW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44>	MWixO\|U5QDd2NB?=
PANC1	MW\GeY5kfGmxbjDBd5NigQ>?	NWrwUI45OSEQvF2=	NEX5VWM1QCBiaB?=		NEPpR5Vld2W\|IH7veEBqdmO{ZXHz[UBqdiCyMkfrbZAyKGenbnWg[ZhxemW\|c3nvci=>	NHHCWnEyPzV6OEe0OC=>
Caco-2	MkH2SpVv[3Srb36gRZN{[Xl?	M1i0dVUh\|ryP	M{TxOlI1KGh?	NWPCcFhWTE2VTx?=	MXHkc4V{KG6xdDDpcoR2[2ViUEKxW2FHOSCpZX7lJIV5eHKnc4Ppc44>	NHfIZZczODF2M{i0NC=>
SCC4	MXLGeY5kfGmxbjDBd5NigQ>?	M1XF[FEh\|ryP	NWT0bpFtOTBibXnu	NYrpOXJlTE2VTx?=	M3\j[4hieyCwbzDh[49vcXO2IHHjeIl3cXS7IHH0JHZFWiCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhS1mSMkSg[4Vv\SCneIDy[ZN{cW:w	NWCzd2pEOjB2NUKyNlU>
A549	NITRTFZHfW6ldHnvckBCe3OjeR?=	NXzNfHRYPSEQvF2=	M3nGXlMhcA>?	NH\O[4hFVVOR	NGPlU2Vld2W\|IH7veEBqdmS3Y3WgZZV1d3CqYXf5JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIFzDN2lK	NWfIU3hQOjB6NUWyNFg>
HCT116	M4q2VmtqdmG\|ZTDBd5NigQ>?	MnjsNE4{KM7:TR?=	NYXrOZQ2OzBiaB?=	M3fUTWROW09?	MlW0[I9meyCwb4SgbY5pcWKrdDDISGFEOSCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm\|dH;u[UBJO0t7IHHj[ZR6dGG2aX;u	NVvZPFN5OjFyOEC2OFc>
HepG2	NH\kfmtHfW6ldHnvckBCe3OjeR?=	Mk\ZNVAh\|ryP	NXfkWJhyOjRiaB?=	MnPVSG1UVw>?	M1L3doRw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYOgZZN{\XO\|ZXSgZZMhcHmyZYLhZ4V1gWyjdHnvckBw\iCyNUO=	NGOzR5kzOTV2OEW4Ni=>
GM11272	NXfKXFFnTnWwY4Tpc44hSXO\|YYm=	MWWwMlEh\|ryP	NWLPcIpjPzJiaB?=	MmjWSG1UVw>?	NELS[FVld2W\|IH7veEBz\WGldHn2ZZRmKE2nQ4CyJI12fGGwdDDlfJBz\XO\|aX;u	M1LoTVIyQDRyN{G2
MDA-MB-231	NIC2elZMcW6jc3WgRZN{[Xl?	MlXnNVAh\|ryP	M2rjTFUhdWmw	M{LUcWROW09?	NVT0OJBP\G:nczDuc5QhcW6qaXLpeEBJTEGFMnG=	MmfENlM1QTN2NEm=
MDA-MB-231	NHzsO2NMcW6jc3WgRZN{[Xl?	M2nWfFEh\|ryP	M3yyXVI1KGh?	Mnv0SG1UVw>?	MmPQ[I9meyCwb4SgbY5pcWKrdDDISGFEPiCjc4Pld5Nm\CCjczDhZ4V1gWyjdHnvckBt\X[nbIOgc4YhfHWkdXzpci=>	M3\NcFI{PDl\|NES5
K562	NWfUVJVUU2mwYYPlJGF{e2G7				NVHWfG5{\G:nczDuc5QhcW6qaXLpeEBJTEGF	Mo\XNlM2QTFzMUG=
Jurkat	NXLjNJpqS3m2b4TvfIlkKEG\|c3H5	M1LHNFIxKM7:TR?=	NIjBbJU4OiCq	NWHDU2VGTE2VTx?=	MXruc{BkgXSxdH;4bYNqfHliYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36=	MYOyOFMxPDN2OB?=
HCT116	MVfBdI9xfG:\|aYOgRZN{[Xl?	NF:wfGc{KM7:TR?=	MU[yOEBp	NYfBSllETE2VTx?=	NWnnbVdI\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwOVMheHKxdHXpckBt\X[nbB?=	M{W0UFI1PzZ4NU[w
KASUMI-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTzTZFmUUN3ME25PU4yPyCwTR?=	MnfBV2FPT0WU
KARPAS-45	M1Kx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M160dWlEPTB;MUezMlg6KG6P	MVLTRW5ITVJ?
BHT-101	M1Xx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH33NnVKSzVyPUK0OE4yQCCwTR?=	MXnTRW5ITVJ?
H9	MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fsUGlEPTB;MkW1MlA1KG6P	NE\0WlZUSU6JRWK=
PA-1	M2\nPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHvN2hKSzVyPUK4Ok4zPiCwTR?=	M4[5SnNCVkeHUh?=
NEC8	NEP6T5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTFTWM2OD1{OEmuN\|ghdk1?	M{KwUnNCVkeHUh?=
MHH-PREB-1	M{LBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTJ7ND61N{BvVQ>?	NUfWc4pRW0GQR1XS
NB7	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjQRXJKSzVyPUO0OU44PCCwTR?=	NYj2eYx4W0GQR1XS
A3-KAW	MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NImwdG5KSzVyPUSwNE42QSCwTR?=	NEja[YtUSU6JRWK=
NB69	MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nDTWlEPTB;NEGxMlcyKG6P	M2LPd3NCVkeHUh?=
EoL-1-cell	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH6zZ5NKSzVyPUS1OFI2KG6P	M3HrWHNCVkeHUh?=
CHP-212	NITNRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDXTWM2OD12NUeuOVMhdk1?	M17SeXNCVkeHUh?=
C2BBe1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTR5Mj6xPUBvVQ>?	NYrYWWRFW0GQR1XS
697	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HWe2lEPTB;NEezMlQyKG6P	M4DBUXNCVkeHUh?=
BCPAP	M3HkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDrWXZnUUN3ME21NFEvPDJibl2=	MVfTRW5ITVJ?
L-363	MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTVyMz6xJI5O	M3;J[nNCVkeHUh?=
ES8	NV;rVGJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTV{Mz61N{BvVQ>?	M2\OWXNCVkeHUh?=
BE-13	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfmVotKSzVyPUWyOk46PiCwTR?=	NH31fllUSU6JRWK=
CTB-1	NIm2TVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlz3TWM2OD13M{euPVIhdk1?	MmXrV2FPT0WU
HD-MY-Z	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTyRW1KSzVyPUWzPE4yOyCwTR?=	NXLyVXZ5W0GQR1XS
NKM-1	NWDvT2h5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPBRYZKSzVyPUW0OE4zPyCwTR?=	NW[y[3FbW0GQR1XS
NCI-H720	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHFZ\|lUUUN3ME21OlAvOThibl2=	MUPTRW5ITVJ?
KY821	MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTV4Mz6yOUBvVQ>?	NEftW\|JUSU6JRWK=
OVCAR-5	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTV5Nj6xNUBvVQ>?	M4jjPXNCVkeHUh?=
CTV-1	NH;YOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTV6MT61OkBvVQ>?	MWTTRW5ITVJ?
P12-ICHIKAWA	NF7rfHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;6TWM2OD13OU[uOVEhdk1?	M2TEOnNCVkeHUh?=
DB	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmL5TWM2OD13OUiuOVchdk1?	MVTTRW5ITVJ?
CHL-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPsSIJIUUN3ME22OFIvODhibl2=	MlzoV2FPT0WU
A4-Fuk	Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXIXFRKSzVyPU[0OE46OSCwTR?=	MXXTRW5ITVJ?
MV-4-11	MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTZ3OT6xJI5O	NFvQSllUSU6JRWK=
RPMI-8226	M1HZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LzdGlEPTB;Nke4MlE5KG6P	MoC4V2FPT0WU
NB14	NEPIT4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PmdWlEPTB;Nkm2Mlk2KG6P	NWWwZo1YW0GQR1XS
DOHH-2	M2HDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrCTWM2OD15ME[uOlghdk1?	NVXWfI9nW0GQR1XS
D-423MG	NGDPUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmntTWM2OD15ME[uPFkhdk1?	NIroWYpUSU6JRWK=
D-283MED	NVXZW4dzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXi4d24yUUN3ME23NVQvOTRibl2=	M{\3O3NCVkeHUh?=
ES1	NGTCVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrXdJdnUUN3ME23NlQvPCCwTR?=	M1H1dXNCVkeHUh?=
GOTO	NI\QNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonVTWM2OD15MkmuNVIhdk1?	M4f1fHNCVkeHUh?=
NCI-H209	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrzTVRKSzVyPUeyPU46KG6P	MoHuV2FPT0WU
MOLT-13	NUjs[\|NsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4e2TWlEPTB;N{O4Mlk5KG6P	Ml\DV2FPT0WU
ATN-1	NIT6SXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTiTWM2OD15NECuNlghdk1?	MX7TRW5ITVJ?
DU-4475	NGLqWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTd3MT65NUBvVQ>?	M{PKfXNCVkeHUh?=
NB10	NUG2UFY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1y3NGlEPTB;N{WxMlkzKG6P	NXfTenJGW0GQR1XS
KG-1	NVvsXoJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFr4WmlKSzVyPUe3OU41PSCwTR?=	NUG3dZY6W0GQR1XS
MOLT-4	M3LhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXLTWM2OD15OEeuOFYhdk1?	NGe0eIVUSU6JRWK=
TE-1	NXXm[YNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTd7MT6xJI5O	M1HTWXNCVkeHUh?=
SBC-1	M1[0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTd7Mz64OEBvVQ>?	NHzz[nBUSU6JRWK=
HEL	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRThyNj6wPEBvVQ>?	NYCzWotCW0GQR1XS
SK-MEL-2	M4G2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\sT2lEPTB;OEC5MlQ1KG6P	NUnPeWdmW0GQR1XS
KU812	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\3Tm1KSzVyPUixN{4yKG6P	NYC3XGhXW0GQR1XS
RPMI-8866	NW[5bG9RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TxdGlEPTB;OEGzMlY4KG6P	MmXKV2FPT0WU
ALL-PO	NFW3dGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrO[4hKSzVyPUixOE43PiCwTR?=	MkGzV2FPT0WU
LU-139	NWPrdFR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF73eZVKSzVyPUiyNk45PiCwTR?=	MYnTRW5ITVJ?
RS4-11	NF\mUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTh\|Mj60OUBvVQ>?	NITMT4RUSU6JRWK=
EW-18	NHnoVJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjZ[JNpUUN3ME24N\|IvQTZibl2=	MlPUV2FPT0WU
P30-OHK	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnSU5JKSzVyPUizOU44KG6P	NH7k[GNUSU6JRWK=
D-566MG	NU\POWI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjWTWM2OD16M{iuOlIhdk1?	M3TYWnNCVkeHUh?=
HSC-4	NFrJbJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTCPIN6UUN3ME24OFYvPTFibl2=	M2fzT3NCVkeHUh?=
QIMR-WIL	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH6z[mJKSzVyPUi2Nk4xOyCwTR?=	MV3TRW5ITVJ?
SW954	M2XQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPkTWM2OD16NkOuNVYhdk1?	NWrnU4t6W0GQR1XS
HGC-27	NFfsZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PkWWlEPTB;OEeyMlM1KG6P	MoTIV2FPT0WU
HH	NVyxXZNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLQTWM2OD16OUSuNVIhdk1?	NXrKNmZTW0GQR1XS
KE-37	MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTSe3NKSzVyPUi5OE43OiCwTR?=	NYTuNmo4W0GQR1XS
SK-N-DZ	NFPw[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTlyMD60N{BvVQ>?	M1rR[nNCVkeHUh?=
J-RT3-T3-5	MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LKdGlEPTB;OUGwMlQ6KG6P	MXnTRW5ITVJ?
A427	MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LhWmlEPTB;OUKwMlg1KG6P	MlTxV2FPT0WU
ECC10	M1vCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTl2NT64O{BvVQ>?	MYrTRW5ITVJ?
EW-1	NYnBcJhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULPWXZmUUN3ME25OFcvOjZibl2=	NUK1fFg4W0GQR1XS
MIA-PaCa-2	MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfDTWM2OD17NEmuNVIhdk1?	NGfjPZVUSU6JRWK=
HCC2218	NIjMN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTl3OD60PEBvVQ>?	NIW2NohUSU6JRWK=
HAL-01	NF3tWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PQfWlEPTB;OU[4MlA1KG6P	NEHafIdUSU6JRWK=
RD	M3vpWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTl5ND60OUBvVQ>?	NGLRe49USU6JRWK=
SK-N-AS	MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTl6OD6xJI5O	MlvYV2FPT0WU
ML-2	Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjXRVM6UUN3ME2xMlAxPDB5IN88US=>	MnrZV2FPT0WU
MEL-HO	NWPvdolPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HqR2lEPTB;MT6wNFU5OiEQvF2=	NHHDeFRUSU6JRWK=
MS-1	M4KzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13RV2lEPTB;MT6wNFYyPyEQvF2=	M{i3enNCVkeHUh?=
NCI-SNU-1	NHrJcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmH4TWM2OD1zLkCyN\|MyKM7:TR?=	MVzTRW5ITVJ?
8505C	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fCN2lEPTB;MT6wNlM{OSEQvF2=	NGHQUGJUSU6JRWK=
MN-60	NF\jVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnr1TWM2OD1zLkCyOlgh\|ryP	M4q2O3NCVkeHUh?=
SAS	NHPVeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTFwMESwPFEh\|ryP	M3HaN3NCVkeHUh?=
EFM-19	NYO3d5BjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLwTWM2OD1zLkC0PFc6KM7:TR?=	MX3TRW5ITVJ?
Ca9-22	MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rwO2lEPTB;MT6wOVExPyEQvF2=	Mmj0V2FPT0WU
NBsusSR	MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPJUYZKSzVyPUGuNFUyPjZizszN	M4e4T3NCVkeHUh?=
NB13	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTFwMEW1NFEh\|ryP	NES4UVZUSU6JRWK=
SF295	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTFwME[2NlQh\|ryP	M3jJNnNCVkeHUh?=
U-2-OS	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjuNmxyUUN3ME2xMlA4QTFzIN88US=>	MWjTRW5ITVJ?
NCI-H526	M3Ti[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vrd2lEPTB;MT6wPFI6OSEQvF2=	NVfNOG9TW0GQR1XS
KMOE-2	M{f0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHlXY57UUN3ME2xMlA6PDJ{IN88US=>	NUS0fGtVW0GQR1XS
RCM-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3uwPWlEPTB;MT6xNlExOiEQvF2=	MWDTRW5ITVJ?
MC116	NIHweIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7abGNKSzVyPUGuNVM3OjFizszN	M1fWWXNCVkeHUh?=
NCI-H1092	NGq1WFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7HTWM2OD1zLkG1OFA3KM7:TR?=	M4\VSnNCVkeHUh?=
EW-3	NVvGeVl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDpPItKSzVyPUGuNVczOTJizszN	M3LvSHNCVkeHUh?=
HCT-116	NGnEWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHZOoRJUUN3ME2xMlE4PzVizszN	MVPTRW5ITVJ?
MC-IXC	NXu2dmE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTFwMUe4PFEh\|ryP	NYnJe21NW0GQR1XS
LB1047-RCC	NHHCWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13oN2lEPTB;MT6xPFMyOiEQvF2=	M3f5W3NCVkeHUh?=
VM-CUB-1	MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrnTFlKSzVyPUGuNVkyODhizszN	MYDTRW5ITVJ?
NB5	NYO3SVV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTFwMUm4OVYh\|ryP	NXfjNWtuW0GQR1XS
SKG-IIIa	MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\1TWM2OD1zLkKzOFY1KM7:TR?=	M{Hnc3NCVkeHUh?=
HO-1-N-1	M1\WR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTITWM2OD1zLkKzPFM2KM7:TR?=	MkHEV2FPT0WU
EFO-27	NFG1bXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTFwMkWwOFMh\|ryP	MnTmV2FPT0WU
MHH-NB-11	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{f0UmlEPTB;MT6yPFMzQSEQvF2=	MUDTRW5ITVJ?
SW620	M3myVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXOTWM2OD1zLkK5NFE5KM7:TR?=	MUXTRW5ITVJ?
MOLT-16	NGLNVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPaR3ZbUUN3ME2xMlI6Pzl5IN88US=>	Ml7DV2FPT0WU
NTERA-S-cl-D1	NFHNSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7qTWM2OD1zLkOxO\|YyKM7:TR?=	NFWzNXZUSU6JRWK=
VA-ES-BJ	M2PFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTFwM{K0O\|ch\|ryP	MV7TRW5ITVJ?
HCC1419	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPtTWM2OD1zLkO0NFI4KM7:TR?=	NGrmWoxUSU6JRWK=
NCI-H69	MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4qyfmlEPTB;MT6zOFEyOiEQvF2=	MULTRW5ITVJ?
DEL	NIXQO\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;sUmlEPTB;MT6zOVE3OiEQvF2=	MUHTRW5ITVJ?
LXF-289	MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDkOYlKSzVyPUGuN\|UzPCEQvF2=	NFPOSJpUSU6JRWK=
EW-11	MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoD1TWM2OD1zLkO2NFI3KM7:TR?=	M2jFPXNCVkeHUh?=
KP-4	M2fpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\z[nlKSzVyPUGuN\|cxQDVizszN	NWXQ[JVNW0GQR1XS
NOS-1	MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTFwNEGxPVQh\|ryP	MX3TRW5ITVJ?
SK-NEP-1	Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzQTWM2OD1zLkSxOlk{KM7:TR?=	MYTTRW5ITVJ?
LAMA-84	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTFwNEO5OFUh\|ryP	MXrTRW5ITVJ?
ES5	NWixVXhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTFwNESzJO69VQ>?	MV7TRW5ITVJ?
HuO9	Mn\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTFwNEWzOlIh\|ryP	NXvEcWdnW0GQR1XS
COLO-684	NEnhcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUGwfYVtUUN3ME2xMlQ3OTF6IN88US=>	NIq4NHRUSU6JRWK=
EW-24	NHHrSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTFwNE[1N\|Eh\|ryP	NGPE[HVUSU6JRWK=
BV-173	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlG4TWM2OD1zLkS3NlkyKM7:TR?=	NWXBb2ZjW0GQR1XS
NCI-H1770	NWrDTppjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\vTJpWUUN3ME2xMlQ5PTN4IN88US=>	M3Hz[XNCVkeHUh?=
HuP-T4	MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTFwNEmzJO69VQ>?	MonJV2FPT0WU
TYK-nu	M4DZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1Hj[2lEPTB;MT60PVg2OSEQvF2=	NVH2RpU{W0GQR1XS
YH-13	M3XMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjpeWpKSzVyPUGuOFk5QTRizszN	NH7SNlFUSU6JRWK=
H4	M33LOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\UfJhqUUN3ME2xMlUxQTF{IN88US=>	NIftTVdUSU6JRWK=
OVCAR-8	M{T0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jXU2lEPTB;MT61OFQ4PyEQvF2=	NFjXXlFUSU6JRWK=
NCI-H23	M4Xsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrl[2tKSzVyPUGuOVQ3PDVizszN	NHHSbHBUSU6JRWK=
ES7	M2HrVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPyOGVkUUN3ME2xMlU1Pzd\|IN88US=>	NUfRR2dRW0GQR1XS
COR-L88	M1G1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTFwNU[0NlQh\|ryP	NEnqXZlUSU6JRWK=
TI-73	NUfHfZg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTFwNUmwOkDPxE1?	NFLZN3dUSU6JRWK=
RT-112	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTFwNUmyPFQh\|ryP	M3jVc3NCVkeHUh?=
HuO-3N1	MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTFwNUmzPFUh\|ryP	NGS2[m9USU6JRWK=
HC-1	M4HDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTFwNUm4OlYh\|ryP	NF:3cGNUSU6JRWK=
HT55	NG\wO3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTFwNkWxN\|Eh\|ryP	NGLOb4RUSU6JRWK=
IA-LM	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfrZZBKSzVyPUGuOlkzPzhizszN	NUXhfYNEW0GQR1XS
EM-2	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjjbI9KSzVyPUGuO\|AxOTRizszN	MX3TRW5ITVJ?
MHH-ES-1	NH:0dIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYKz[o1pUUN3ME2xMlcxPDN3IN88US=>	NYnGbGVUW0GQR1XS
CAL-27	Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnpO2xUUUN3ME2xMlcxPjJzIN88US=>	M3Xx[XNCVkeHUh?=
COLO-800	NWnVUnZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvQPFJKSzVyPUGuO\|EyPzlizszN	MVXTRW5ITVJ?
HCE-T	M33GVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH:0RVlKSzVyPUGuO\|E2KM7:TR?=	NFTWWZVUSU6JRWK=
CAMA-1	NHnFVYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDnTWM2OD1zLkexPVcyKM7:TR?=	NHHZO\|lUSU6JRWK=
LOXIMVI	NFzKd5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoKwTWM2OD1zLkeyNVEh\|ryP	NFzsUHFUSU6JRWK=
NH-12	NWnYb3M1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLLVJRKSzVyPUGuO\|I3QTFizszN	M3XtS3NCVkeHUh?=
TCCSUP	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3hTplrUUN3ME2xMlczQDJ7IN88US=>	M{TvT3NCVkeHUh?=
MDA-MB-361	M3:wTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfjWY52UUN3ME2xMlc{OTV5IN88US=>	MlX2V2FPT0WU
EW-16	NFyxfoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTFwN{SxNFch\|ryP	M4TFcHNCVkeHUh?=
SNU-423	MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\FboVKSzVyPUGuO\|U5OjdizszN	MXvTRW5ITVJ?
Daoy	NUL4R3NQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2K4VGlEPTB;MT63OlMyQSEQvF2=	M1nlNXNCVkeHUh?=
ES4	M{jqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYm5TlZMUUN3ME2xMlc5PzRzIN88US=>	M2C2VHNCVkeHUh?=
PFSK-1	MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17vZmlEPTB;MT64NFM4KM7:TR?=	NYPTd4xxW0GQR1XS
ES3	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnzb\|J2UUN3ME2xMlgzPjhzIN88US=>	NWfWXHNVW0GQR1XS
ONS-76	NEHZWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7ZTXdKSzVyPUGuPFI5QTdizszN	M{XrVnNCVkeHUh?=
JVM-3	NXezboIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTFwOEW0OVEh\|ryP	NWfme\|FGW0GQR1XS
OS-RC-2	NE\QbZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYryUIxkUUN3ME2xMlg4OTVzIN88US=>	M4DhWnNCVkeHUh?=
COLO-320-HSR	NYTWPIZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmKzTWM2OD1zLki4NVk4KM7:TR?=	MmLLV2FPT0WU
HN	MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\PUmlEPTB;MT64PFczPSEQvF2=	MUjTRW5ITVJ?
HT	NWDZNVdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrvTWM2OD1zLki4PVQ4KM7:TR?=	M3LGbHNCVkeHUh?=
LoVo	NGSzO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nufmlEPTB;MT64PVgyKM7:TR?=	M3y2UnNCVkeHUh?=
CGTH-W-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjzWXNpUUN3ME2xMlg6QTR4IN88US=>	M{ftNHNCVkeHUh?=
NB6	NU\v[3JNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUOxW2RHUUN3ME2xMlkyOjl6IN88US=>	NHv3UpZUSU6JRWK=
EW-22	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILjS\|NKSzVyPUGuPVI5QDdizszN	Mme3V2FPT0WU
ES6	NFXXUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXwTWM2OD1zLkmzOlMyKM7:TR?=	Mm\SV2FPT0WU
SCC-15	NH[yXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mle5TWM2OD1zLkmzPFE6KM7:TR?=	M1;hdnNCVkeHUh?=
HL-60	NVH1[\|VXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLBTWM2OD1zLkmzPVAzKM7:TR?=	NHvQdo9USU6JRWK=
human HOP-92	M2XXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\4Xo1NUUN3ME2xMlk1ODZ3IN88US=>	NFW0OpZUSU6JRWK=
SW626	NXjIVHQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHn4V5FKSzVyPUGuPVQ5QTlizszN	NYDzSpJyW0GQR1XS
HEC-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2H2Z2lEPTB;MT65OVM3KM7:TR?=	MXXTRW5ITVJ?
LB2241-RCC	MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrrNVFKUUN3ME2xMlk5OjNzIN88US=>	MYTTRW5ITVJ?
Ramos-2G6-4C10	NGfFV29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjZTWM2OD1zLkm5OFk{KM7:TR?=	NGnrWGhUSU6JRWK=
A101D	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTJwMkCzNFMh\|ryP	M4XIZnNCVkeHUh?=
NCI-H446	NY\DT4l2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7RcWlKSzVyPUKuNFQ2QTlizszN	MWLTRW5ITVJ?
SBC-5	NIrTW2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3DTWM2OD1{LkC2NVQ4KM7:TR?=	NW[x[2hJW0GQR1XS
HOS	M2DReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTJwMEe2OVMh\|ryP	Mof6V2FPT0WU
K5	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\FWmQ{UUN3ME2yMlA4QDFzIN88US=>	NU\rXFllW0GQR1XS
HLE	NHn5d\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljVTWM2OD1{LkC4OVI6KM7:TR?=	M3LuTXNCVkeHUh?=
HSC-2	M2rmVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYe3cVBQUUN3ME2yMlEzQDl6IN88US=>	NYHI[2dXW0GQR1XS
LCLC-97TM1	MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\NdnIyUUN3ME2yMlE1PTh\|IN88US=>	NG\J[VNUSU6JRWK=
DMS-273	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;SOWlEPTB;Mj6xOFg{PyEQvF2=	M1njSHNCVkeHUh?=
TE-8	M1zzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTJwMUW3OlUh\|ryP	NHLrfVdUSU6JRWK=
DSH1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rq[mlEPTB;Mj6xOlM6QCEQvF2=	M4O0THNCVkeHUh?=
CAL-51	M2T2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorzTWM2OD1{LkG2Olk6KM7:TR?=	Ml\RV2FPT0WU
IST-SL1	NWHQZpJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLvTWM2OD1{LkG2PFQ1KM7:TR?=	MlLhV2FPT0WU
GCT	MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnv4TWM2OD1{LkG3O\|ch\|ryP	Ml\DV2FPT0WU
SW948	NFXoNnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfWXJZYUUN3ME2yMlE5PDV4IN88US=>	MVPTRW5ITVJ?
NOMO-1	Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGX0fnBKSzVyPUKuNVk{OTdizszN	MlzoV2FPT0WU
C8166	NHrDSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfucppjUUN3ME2yMlIyOzN2IN88US=>	NVzKTHpbW0GQR1XS
OC-314	M2Xre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYWyS\|JVUUN3ME2yMlI{OjV7IN88US=>	M4LpNnNCVkeHUh?=
CAL-39	NGWzVnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGKxW\|dKSzVyPUKuNlM3OjZizszN	M33IdHNCVkeHUh?=
MDA-MB-453	M1XydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{L1OGlEPTB;Mj6yOFI4PSEQvF2=	NXniVFhCW0GQR1XS
A673	NVHyZ29CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fVbGlEPTB;Mj6yOVg3OiEQvF2=	M2HWfnNCVkeHUh?=
HTC-C3	NWP3XWtVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDnOphEUUN3ME2yMlI3QDVizszN	M1\5NnNCVkeHUh?=
NCI-H1666	M3H3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTJwMkixNVEh\|ryP	M2nQ[nNCVkeHUh?=
PSN1	Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnFbG1EUUN3ME2yMlI5QTF\|IN88US=>	MmfSV2FPT0WU
GI-1	NX3NZpdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3XOFhyUUN3ME2yMlMxPTR\|IN88US=>	MmXDV2FPT0WU
HuH-7	MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jtd2lEPTB;Mj6zNFY{PyEQvF2=	MWPTRW5ITVJ?
JAR	NWraepJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTJwM{G5PFch\|ryP	NHL4ZnFUSU6JRWK=
5637	NFztSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTJwM{KxNlkh\|ryP	MXHTRW5ITVJ?
GB-1	M1L2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXIW3BGUUN3ME2yMlMzOzN3IN88US=>	NWnSW5UyW0GQR1XS
KP-N-YS	MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPG[4pKSzVyPUKuN\|I3OTVizszN	NUe1WFVyW0GQR1XS
OAW-42	NXn2d21DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEK3eVNKSzVyPUKuN\|M1OTZizszN	NHfCeYRUSU6JRWK=
8-MG-BA	NH\EflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jyWGlEPTB;Mj6zN\|kxPiEQvF2=	NFfZ[XNUSU6JRWK=
RH-18	MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTJwM{WwNlIh\|ryP	NIG3U4NUSU6JRWK=
NCI-H1155	NF\GVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDJRnRKSzVyPUKuN\|Y4OjVizszN	NIXTcYZUSU6JRWK=
NB17	MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWj3WFUzUUN3ME2yMlM5OjR\|IN88US=>	M1joV3NCVkeHUh?=
NCI-H1437	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\zTWM2OD1{LkSxPFc{KM7:TR?=	NFH3dZlUSU6JRWK=
SN12C	M2TSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\XZYppUUN3ME2yMlQ{OjF2IN88US=>	NUjVZ\|lDW0GQR1XS
HSC-3	MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHVV2s5UUN3ME2yMlQ1PTB7IN88US=>	NHTqc\|hUSU6JRWK=
GAMG	NGOyZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPITWM2OD1{LkS0OVYyKM7:TR?=	MnHmV2FPT0WU
HT-1080	NVzrbI5FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTaTXI2UUN3ME2yMlQ1QDZ2IN88US=>	MW\TRW5ITVJ?
A549	NIe5fGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTxem03UUN3ME2yMlQ1QDl\|IN88US=>	MXTTRW5ITVJ?
KNS-62	M3K1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTnTWM2OD1{LkS1NFYyKM7:TR?=	NEjNXo1USU6JRWK=
YKG-1	NX7BSYdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPDTmY{UUN3ME2yMlQ2PDN5IN88US=>	M2LWPHNCVkeHUh?=
LU-134-A	NX31N3prT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rkc2lEPTB;Mj60O\|AxQCEQvF2=	MWLTRW5ITVJ?
FADU	NUHtZlFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\qW2lEPTB;Mj60O\|E3OiEQvF2=	NISxNJVUSU6JRWK=
TGBC11TKB	NVjITJRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPGTWM2OD1{LkS3NVc4KM7:TR?=	MX7TRW5ITVJ?
HT-3	NFW4W5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPUfVhXUUN3ME2yMlQ6PTN3IN88US=>	MVPTRW5ITVJ?
NCI-H2170	NIfKNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIT1XWlKSzVyPUKuOVA2PDlizszN	MmfDV2FPT0WU
Mo-T	NIPGSWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDBTIhKSzVyPUKuOVA6OjdizszN	M{SzV3NCVkeHUh?=
CCRF-CEM	M2HHWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrTU\|dKSzVyPUKuOVMxPDNizszN	MlLKV2FPT0WU
KU-19-19	NHSzOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDY[YFIUUN3ME2yMlU{PTF\|IN88US=>	MWHTRW5ITVJ?
NCI-H1048	NVrEUHgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XneGlEPTB;Mj61OVAzPSEQvF2=	NXLkVYJ6W0GQR1XS
KOSC-2	NUD2Z2l3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLzTWM2OD1{LkW2NFc3KM7:TR?=	NVXCZ5FKW0GQR1XS
A431	NUK0dmR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7iN3BKSzVyPUKuOVY{OzVizszN	NHzNS3BUSU6JRWK=
COR-L23	M3\oS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTJwNUi1OlYh\|ryP	M{nOXHNCVkeHUh?=
MKN28	M1rsOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTJwNUmwN\|ch\|ryP	MYXTRW5ITVJ?
22RV1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfJXoNSUUN3ME2yMlU6Ojd2IN88US=>	MorUV2FPT0WU
ABC-1	NVfOWpNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TvTGlEPTB;Mj62NFQ3KM7:TR?=	MmOzV2FPT0WU
NCI-H2126	MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGq0c5ZKSzVyPUKuOlA6QDRizszN	M4XL[HNCVkeHUh?=
DoTc2-4510	M2DmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHP6[oVKSzVyPUKuOlIyQDVizszN	MVXTRW5ITVJ?
SCC-4	MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{f1OGlEPTB;Mj62N\|AyOiEQvF2=	NXvqVXRiW0GQR1XS
NCI-H661	NIfSWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTJwNkSwPFUh\|ryP	NVvEZVZzW0GQR1XS
RPMI-2650	NX7VdYl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXS1[lVDUUN3ME2yMlY1OTR\|IN88US=>	M4DCXHNCVkeHUh?=
NCI-H510A	M1jsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTJwNkS0NlYh\|ryP	NX3FZlNUW0GQR1XS
BPH-1	M{LYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXETWM2OD1{Lk[1PFUh\|ryP	MVzTRW5ITVJ?
M14	NEL2XVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkm1TWM2OD1{Lk[2PVk{KM7:TR?=	NEPYZ4dUSU6JRWK=
G-402	M32xXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfycJVZUUN3ME2yMlcxPDVzIN88US=>	MVLTRW5ITVJ?
AsPC-1	Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnh[4JRUUN3ME2yMlcyOTdizszN	MVzTRW5ITVJ?
NB12	NFO1SFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTJwN{G3NUDPxE1?	MmT0V2FPT0WU
SK-HEP-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTJwN{SzPVEh\|ryP	NYPOZpA6W0GQR1XS
U-266	NVnD[VlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\r[mlEPTB;Mj63O\|EzOSEQvF2=	MULTRW5ITVJ?
AM-38	NXHiZ4h4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3P2b2lEPTB;Mj63O\|M2PSEQvF2=	NFj3SFZUSU6JRWK=
PC-14	NIrHPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jnNWlEPTB;Mj64NFUyKM7:TR?=	NYnaTZBFW0GQR1XS
EGI-1	NFX5dnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nMUWlEPTB;Mj64NVc1OyEQvF2=	M4H0enNCVkeHUh?=
LS-411N	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF6zcJRKSzVyPUKuPFI{OyEQvF2=	NWj3WGRQW0GQR1XS
BFTC-905	Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHoTWM2OD1{Lki1OVI{KM7:TR?=	MX7TRW5ITVJ?
CaR-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7oTWM2OD1{Lki2JO69VQ>?	M1\hPXNCVkeHUh?=
NCI-H292	NHWzPXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4KyPWlEPTB;Mj64OlU6PiEQvF2=	NEn5UnRUSU6JRWK=
8305C	M{S3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXNO5N{UUN3ME2yMlg3PjR3IN88US=>	NUHWfoZHW0GQR1XS
SNU-449	NV\zepZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUiwV5ZQUUN3ME2yMlg6OTh{IN88US=>	M2CzeXNCVkeHUh?=
LCLC-103H	MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3remhIUUN3ME2yMlkxPDN6IN88US=>	M1TOT3NCVkeHUh?=
SW1573	NYX4dYcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILxN2NKSzVyPUKuPVYxQDJizszN	MmjIV2FPT0WU
MLMA	NHnOSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTJwOU[3NVch\|ryP	NVnPeJpRW0GQR1XS
NCI-H1355	NUDGb3NtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTNwMEC3PVYh\|ryP	MVjTRW5ITVJ?
RMG-I	NEnzS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPpTnk4UUN3ME2zMlAzPTl{IN88US=>	MlroV2FPT0WU
BB65-RCC	MmK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkD2TWM2OD1\|LkCzN\|E1KM7:TR?=	M4PofXNCVkeHUh?=
PC-3	NXvUdZpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTwTWM2OD1\|LkCzPFc1KM7:TR?=	MlTxV2FPT0WU
SF268	MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTNwMES1NlMh\|ryP	M4TYcnNCVkeHUh?=
NCI-H810	MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYOxOVdGUUN3ME2zMlA1QDJ\|IN88US=>	NVriXlY2W0GQR1XS
MEG-01	NGPxToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\BTWlEPTB;Mz6wOlE3PCEQvF2=	NI\hbWhUSU6JRWK=
SW13	Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHIcZF[UUN3ME2zMlA4QDR5IN88US=>	Ml\1V2FPT0WU
RH-1	NXnLW4luT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zZZWlEPTB;Mz6xNFI4QCEQvF2=	M1qydHNCVkeHUh?=
GT3TKB	M4rJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1P4VWlEPTB;Mz6xNVI5OyEQvF2=	M2W5eHNCVkeHUh?=
TK10	NF3WZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTNwMUO3NlQh\|ryP	NGHGXIlUSU6JRWK=
T-24	M1rUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\XTWM2OD1\|LkG1NFch\|ryP	M4iwSHNCVkeHUh?=
A498	NILheJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUSxZWxUUUN3ME2zMlIxQDdzIN88US=>	MXHTRW5ITVJ?
GR-ST	M1y2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTBT5BKSzVyPUOuNlIyOzlizszN	MlL1V2FPT0WU
LB2518-MEL	NXG3[pg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYOyZ3VrUUN3ME2zMlIzOzl6IN88US=>	MUjTRW5ITVJ?
T47D	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLVTWM2OD1\|LkKzOlI4KM7:TR?=	MoKxV2FPT0WU
NCI-H1651	MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfwfWt7UUN3ME2zMlI1PjR2IN88US=>	NWjKXVJwW0GQR1XS
EC-GI-10	NXXKPZNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlX3TWM2OD1\|LkK2NVU{KM7:TR?=	NHjL[IJUSU6JRWK=
HT-29	MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojQTWM2OD1\|LkK2OlE1KM7:TR?=	NVvCXlJPW0GQR1XS
GI-ME-N	M{\nWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXXdmhKSzVyPUOuNlk2OTFizszN	NGTrWW9USU6JRWK=
SW756	NGjKSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TsUWlEPTB;Mz6yPVYzQSEQvF2=	M{eyWHNCVkeHUh?=
RKO	NFPkUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfGUldUUUN3ME2zMlMxPzV5IN88US=>	M1jBVHNCVkeHUh?=
NCI-H1563	NILrVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{P2cWlEPTB;Mz6zN\|AyQCEQvF2=	Ml\pV2FPT0WU
DJM-1	NHj5bVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TuWmlEPTB;Mz6zO\|Y4PCEQvF2=	M3nUSnNCVkeHUh?=
L-428	M{\OO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XlW2lEPTB;Mz60NFA1PSEQvF2=	MXfTRW5ITVJ?
NCI-H2122	NYfhTolmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;GOIVKSzVyPUOuOFE{OTJizszN	MmTZV2FPT0WU
Ca-Ski	NImxbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\PU2lEPTB;Mz60OVQ{KM7:TR?=	MYfTRW5ITVJ?
639-V	MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIq1c49KSzVyPUOuOFYxPTdizszN	MVjTRW5ITVJ?
SW1116	NGLDVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTNwNE[yOlkh\|ryP	NVXMcoFJW0GQR1XS
DMS-114	NYLEdmd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrSTJhKSzVyPUOuOFcxPjZizszN	MVXTRW5ITVJ?
MZ2-MEL	NYnJfnRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTNwNEe2PFEh\|ryP	M1Kxb3NCVkeHUh?=
COLO-829	MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXWTWM2OD1\|LkWwNFc{KM7:TR?=	M3zqR3NCVkeHUh?=
J82	M3vGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{KyO2lEPTB;Mz61NFU4KM7:TR?=	MlrCV2FPT0WU
EW-13	Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnXV41KSzVyPUOuOVI2OSEQvF2=	M2noS3NCVkeHUh?=
RXF393	NGnxZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjrPXBKSzVyPUOuOVMzQTRizszN	MVTTRW5ITVJ?
CAL-62	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTNwNUS1NVQh\|ryP	MofjV2FPT0WU
OCUB-M	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYW3WVlSUUN3ME2zMlU1PjZ3IN88US=>	M{\KTnNCVkeHUh?=
BT-474	Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHO4fHdKSzVyPUOuOlM{OSEQvF2=	MkLtV2FPT0WU
KYSE-180	NGf2ZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DsU2lEPTB;Mz62N\|M4OiEQvF2=	MoPTV2FPT0WU
NCI-H650	MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PvWGlEPTB;Mz62OFI5PyEQvF2=	MXrTRW5ITVJ?
Detroit562	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlz5TWM2OD1\|Lk[1NFIzKM7:TR?=	MXLTRW5ITVJ?
SW48	M1;CZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTNwNkW2OVch\|ryP	MYPTRW5ITVJ?
KYSE-450	NV:5flRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTNwNki1PFIh\|ryP	MofBV2FPT0WU
KYSE-510	MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTNwN{KxPFEh\|ryP	M1Hk[3NCVkeHUh?=
GP5d	NIHJUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LKNmlEPTB;Mz63Nlk2KM7:TR?=	MXnTRW5ITVJ?
RPMI-7951	NIeyN\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTNwN{S3NlMh\|ryP	NUH6[ow4W0GQR1XS
Becker	M1TpPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnETWM2OD1\|Lke1NFEzKM7:TR?=	MkXrV2FPT0WU
WM-115	NXLCRm0zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTNwN{ixPVUh\|ryP	MnHhV2FPT0WU
G-401	M2q4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;uXpFKSzVyPUOuO\|kxQDVizszN	MmPSV2FPT0WU
PANC-08-13	M{Tsc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvLSG5KSzVyPUOuO\|k3ODJizszN	MWfTRW5ITVJ?
SW982	NUDaT4dvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\aTWM2OD1\|LkiwOVUyKM7:TR?=	NYnvd3NDW0GQR1XS
D-263MG	NXzlR2Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1KxTGlEPTB;Mz64NlA2OSEQvF2=	NH7TbXZUSU6JRWK=
KM-H2	NG\4eYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTNwOEK2NlQh\|ryP	NX\rR3p6W0GQR1XS
SK-MEL-3	M1;xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVr2UY57UUN3ME2zMlgzQDRzIN88US=>	M3jGOnNCVkeHUh?=
NCI-H1581	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7NTWM2OD1\|Lki0OFg5KM7:TR?=	NIfNW49USU6JRWK=
LS-123	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3eyU2lEPTB;Mz64O\|kxQSEQvF2=	NVPp[WxJW0GQR1XS
CAKI-1	Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mon1TWM2OD1\|Lki5NFUzKM7:TR?=	M4Lue3NCVkeHUh?=
MEL-JUSO	MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfzTWM2OD1\|Lki5NVU{KM7:TR?=	M2PvZnNCVkeHUh?=
HCE-4	NVHhbmI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTNwOUG2OlMh\|ryP	M1m4TXNCVkeHUh?=
TE-10	M3XpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoG3TWM2OD1\|LkmyNFEh\|ryP	MofUV2FPT0WU
OVCAR-4	MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXW4RWhpUUN3ME2zMlkzQDh7IN88US=>	NEDmXY5USU6JRWK=
ETK-1	NYPHRWM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13CXWlEPTB;Mz65OFY{PSEQvF2=	NXrRUo5kW0GQR1XS
A2780	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3LUJNsUUN3ME20MlA2QTZ4IN88US=>	MmjWV2FPT0WU
LU-65	NHGxcJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1K3OWlEPTB;ND6wO\|Y{OyEQvF2=	M{jn[XNCVkeHUh?=
BHY	NV;HToNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zpVGlEPTB;ND6xNlQ6PSEQvF2=	M37KdnNCVkeHUh?=
COR-L105	M2r0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4S5eWlEPTB;ND6xN\|A2OSEQvF2=	NWL3Tpp1W0GQR1XS
CAL-12T	MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjhTWM2OD12LkGzNVA{KM7:TR?=	MWTTRW5ITVJ?
SCH	M4jETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlT2TWM2OD12LkG1O\|Q{KM7:TR?=	M3LzfXNCVkeHUh?=
CW-2	M1jMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnTdVNFUUN3ME20MlE6ODBzIN88US=>	MkLBV2FPT0WU
HCC1806	M2G4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;yZ2NKUUN3ME20MlIxOzF{IN88US=>	MnrSV2FPT0WU
KP-N-YN	M4DlZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;0RpdIUUN3ME20MlIxQTJ5IN88US=>	MmrZV2FPT0WU
T98G	MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7QcmZKSzVyPUSuNlIyPTdizszN	NXrXdll7W0GQR1XS
CAL-54	MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jqSmlEPTB;ND6yNlM5OSEQvF2=	MnnSV2FPT0WU
CAL-33	NVnsVFRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofFTWM2OD12LkKzNFY1KM7:TR?=	M2fMV3NCVkeHUh?=
SNU-C2B	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2Phd2lEPTB;ND6yOFc3QSEQvF2=	M2W5S3NCVkeHUh?=
NUGC-3	NEWxWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTRwMkW1NFUh\|ryP	MVrTRW5ITVJ?
DOK	M2Ht[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGe3SFRKSzVyPUSuNlY2QTNizszN	MUXTRW5ITVJ?
MMAC-SF	MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rMWmlEPTB;ND6yOlg2QSEQvF2=	MYjTRW5ITVJ?
KYSE-70	NGL6coZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PGPGlEPTB;ND6yPVM1KM7:TR?=	Mk\yV2FPT0WU
A204	NYH2UYgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTRwM{W4NFMh\|ryP	NYLld\|ZRW0GQR1XS
SCC-25	MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjRfI9KSzVyPUSuN\|U5OTlizszN	MljGV2FPT0WU
EPLC-272H	M1XqZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vmd2lEPTB;ND6zPFk2KM7:TR?=	NYDYdnRyW0GQR1XS
CAL-120	M3rmWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUWxenZHUUN3ME20MlM5QTl{IN88US=>	MYjTRW5ITVJ?
LS-513	M2LEbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rQfGlEPTB;ND60NlE6QCEQvF2=	NF\l[FBUSU6JRWK=
CAPAN-1	M{jpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;ETZZKSzVyPUSuOFI{QDJizszN	MnPnV2FPT0WU
ESS-1	NHrlXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XtfmlEPTB;ND60NlczPCEQvF2=	NH3a[WRUSU6JRWK=
GMS-10	M3vzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rhTWlEPTB;ND60NlgyQSEQvF2=	Mkf6V2FPT0WU
NCI-N87	NHu4dHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{Sz[2lEPTB;ND61NFg3QCEQvF2=	NHPFVJpUSU6JRWK=
HMV-II	MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEL4VnhKSzVyPUSuOVE4OyEQvF2=	NHXr[JNUSU6JRWK=
COLO-741	NYTPcFlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHrU4pKSzVyPUSuOVU6QTRizszN	MWHTRW5ITVJ?
MKN45	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTRwNUe3N\|Ih\|ryP	MUnTRW5ITVJ?
OAW-28	NVLKN\|dWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH[4N41KSzVyPUSuOVg{QThizszN	NWPKeppqW0GQR1XS
OCI-AML2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rUUGlEPTB;ND62OVI{QCEQvF2=	MoXjV2FPT0WU
MDA-MB-231	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvrTWM2OD12LkewNlQ{KM7:TR?=	NWXUNpJmW0GQR1XS
NCI-H1648	NFnyUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnITWM2OD12LkeyNlc{KM7:TR?=	NYnEPFJUW0GQR1XS
NCI-H1792	NVjwdo9YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LvdmlEPTB;ND63OlExPyEQvF2=	MV;TRW5ITVJ?
GCIY	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTRwN{e0NlQh\|ryP	NXnk[nV[W0GQR1XS
Hs-578-T	NET1NJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTRwN{e2OVUh\|ryP	NFu4XmtUSU6JRWK=
SW962	MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLNV3ZTUUN3ME20Mlc5ODFzIN88US=>	Mo\KV2FPT0WU
NCI-H630	NIP0[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zNTGlEPTB;ND63PFA5OSEQvF2=	Mo\UV2FPT0WU
786-0	M3PWTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTPbVh5UUN3ME20Mlc5Pzd\|IN88US=>	NIjTO5BUSU6JRWK=
FTC-133	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{exOWlEPTB;ND63PVI3OyEQvF2=	NFjrNlRUSU6JRWK=
BT-20	Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\6O3lNUUN3ME20Mlc6PDJ7IN88US=>	NWj5RmF1W0GQR1XS
Mewo	NHTpcotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\TTWM2OD12LkixO\|Q4KM7:TR?=	M2fKRXNCVkeHUh?=
SW780	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTRwOEW3OlYh\|ryP	NHvXOZlUSU6JRWK=
OE33	NXTvcGJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HDeGlEPTB;ND64O\|cyOyEQvF2=	M{T6V3NCVkeHUh?=
HCC1569	MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDDTWM2OD12Lki4OFU5KM7:TR?=	NIXEPFVUSU6JRWK=
TE-6	NYnWOY02T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\FWo15UUN3ME20Mlk{QTd5IN88US=>	NUPE[oRzW0GQR1XS
SK-N-FI	NFzCcG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDKb4xXUUN3ME20Mlk1PDJzIN88US=>	NYq0R3dYW0GQR1XS
PANC-03-27	NEHVc2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrqbHFKSzVyPUSuPVk6PjJizszN	MVnTRW5ITVJ?
MCF7	Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTVwMEC3N\|gh\|ryP	Mly4V2FPT0WU
UACC-257	MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTJTWM2OD13LkCyPFQ2KM7:TR?=	MXPTRW5ITVJ?
SW1088	NYe0e21tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XQSWlEPTB;NT6wNlk1PCEQvF2=	M3L6Z3NCVkeHUh?=
A704	NEe4dFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTVwMEOwOkDPxE1?	M3\UXHNCVkeHUh?=
A2058	Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTVwMEW5NFgh\|ryP	NXfYXG1rW0GQR1XS
Calu-3	NHTLcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DTUmlEPTB;NT6wOlQ2OiEQvF2=	Mlj0V2FPT0WU
RERF-LC-MS	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjmbY5KSzVyPUWuNFY6ODNizszN	M3HOe3NCVkeHUh?=
AU565	MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHW1bGxKSzVyPUWuNFk4ODJizszN	MYrTRW5ITVJ?
DMS-79	NFO5XZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDxTWM2OD13LkGzPFg{KM7:TR?=	MUPTRW5ITVJ?
DK-MG	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17zfmlEPTB;NT6xPFQ{QCEQvF2=	M3LZWHNCVkeHUh?=
HuCCT1	MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rvRmlEPTB;NT6yN\|g2PiEQvF2=	M{S5ZXNCVkeHUh?=
HT-144	NWj4[ZV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPO[HQ6UUN3ME21MlI1QTh5IN88US=>	M4mxSXNCVkeHUh?=
M059J	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTYVnlOUUN3ME21MlI2PzZizszN	MkjNV2FPT0WU
COLO-792	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnzR45DUUN3ME21MlI3OzV4IN88US=>	MlTPV2FPT0WU
SF539	NYTtbGR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTsdW5xUUN3ME21MlI3PjN{IN88US=>	NV3Ne2l2W0GQR1XS
SK-UT-1	M163b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4X3U2lEPTB;NT6yO\|c2OSEQvF2=	NWHnO\|lzW0GQR1XS
NCI-H1703	NV;IUnpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXpWYFKSzVyPUWuN\|U5OjZizszN	NFzmRYpUSU6JRWK=
SW837	M3HvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nDcWlEPTB;NT6zO\|g4QCEQvF2=	NELoW25USU6JRWK=
U251	NXSxVndNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfZTWM2OD13LkO5NFk3KM7:TR?=	Mkn5V2FPT0WU
SW1710	M4\HU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33XXGlEPTB;NT60NVU2PCEQvF2=	NIrlZ5ZUSU6JRWK=
NCI-H1299	Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTVwNE[zN\|Uh\|ryP	NESyXWlUSU6JRWK=
RVH-421	NELhSlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;KVWlEPTB;NT60PVkxQCEQvF2=	NGXUdFhUSU6JRWK=
UM-UC-3	NGm1WYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHO0epFKSzVyPUWuOlI3PTFizszN	MYHTRW5ITVJ?
MDA-MB-175-VII	M{DSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDjXYFKSzVyPUWuOlQxPDFizszN	M{DTd3NCVkeHUh?=
KYSE-270	NHq0SI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTVwNk[wN\|Eh\|ryP	Mnv1V2FPT0WU
COLO-668	NInrPWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjXTWM2OD13LkexN\|Ih\|ryP	NYPHN2hlW0GQR1XS
LN-405	MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGH3eoJKSzVyPUWuO\|MxQDVizszN	NHHNPHFUSU6JRWK=
HT-1376	M4L5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTpOoJKSzVyPUWuO\|gxPTJizszN	NIPDOolUSU6JRWK=
769-P	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfLeJE1UUN3ME21Mlg3PzF6IN88US=>	NGKy[4NUSU6JRWK=
HuP-T3	NH\D[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHGTWM2OD13Lki4Olc4KM7:TR?=	NXPG[JRTW0GQR1XS
MDA-MB-415	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfZ[5JVUUN3ME21MlkzOTN7IN88US=>	M2H5SXNCVkeHUh?=
MKN7	M2XheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nXbmlEPTB;NT65PFgh\|ryP	M360Z3NCVkeHUh?=
KS-1	NWnNVHVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTVwOUi4N\|Yh\|ryP	MULTRW5ITVJ?
647-V	NFfpU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjMfGN1UUN3ME21Mlk6OTR6IN88US=>	NV3w[FFsW0GQR1XS
COLO-679	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3XTJBKSzVyPU[uNFAzPTVizszN	NFnRWZVUSU6JRWK=
AN3-CA	NV7mTW9uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4W2VGlEPTB;Nj6wN\|Q1OSEQvF2=	NWPxW4JQW0GQR1XS
C32	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTZwMUOwN\|Qh\|ryP	Mn:0V2FPT0WU
KM12	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\Heml2UUN3ME22MlI1ODl7IN88US=>	M1KyeXNCVkeHUh?=
KINGS-1	NFLyZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfQTWM2OD14LkK2NVUzKM7:TR?=	NVnwSZYzW0GQR1XS
KYSE-410	MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTZwM{C2OFUh\|ryP	Mm\sV2FPT0WU
HPAF-II	NGOzWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvzbFRKSzVyPU[uN\|U1QCEQvF2=	NVfaW4lLW0GQR1XS
LAN-6	M37pOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvi[5RKSzVyPU[uOFk3OzFizszN	MlnNV2FPT0WU
LU-99A	NYTVTFdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTZwNUW5PFkh\|ryP	M{e0W3NCVkeHUh?=
SJSA-1	M2\1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELUOXlKSzVyPU[uOVY{PDdizszN	M1[1VnNCVkeHUh?=
MSTO-211H	NI\jdmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlexTWM2OD14LkeyNlM{KM7:TR?=	M3rXNXNCVkeHUh?=
SW900	NUX1NoV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTZwN{[yNlEh\|ryP	MX3TRW5ITVJ?
LNCaP-Clone-FGC	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDrfJJEUUN3ME22MlgxPDB\|IN88US=>	M1frNnNCVkeHUh?=
OMC-1	NYTlN2N7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{j4c2lEPTB;Nj64OVQxOiEQvF2=	NIDTOppUSU6JRWK=
IST-MEL1	M4jVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;MTWM2OD14Lki5OlY6KM7:TR?=	MUDTRW5ITVJ?
TE-9	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2T0O2lEPTB;Nj64PVg1PyEQvF2=	NWj2OI1SW0GQR1XS
NCI-H2030	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLjbGM{UUN3ME22MlkyOjJ4IN88US=>	MVfTRW5ITVJ?
BFTC-909	Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHETWM2OD15LkCwOlQyKM7:TR?=	MVTTRW5ITVJ?
NCI-SNU-5	NH7EW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTdwMEKxOVkh\|ryP	M{DmZnNCVkeHUh?=
TE-5	NIjDTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTdwMEK4PFEh\|ryP	M2\DUHNCVkeHUh?=
SK-MES-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTdwMEW0Nlch\|ryP	M{PURnNCVkeHUh?=
SHP-77	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHCTWM2OD15LkGzPVUzKM7:TR?=	M4rjbnNCVkeHUh?=
NCI-H1623	NYr5Wm82T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHn0dHZKSzVyPUeuNVQxPzJizszN	NYfpdVVDW0GQR1XS
TE-11	M4XyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHf2RWJKSzVyPUeuNVUyQDRizszN	MVnTRW5ITVJ?
EKVX	MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFy2[4JKSzVyPUeuNVkzPjdizszN	NYPSfmFRW0GQR1XS
OVCAR-3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIn3PWJKSzVyPUeuNlEyOzNizszN	Ml7jV2FPT0WU
C3A	NHrPfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlW0TWM2OD15LkO0OVIh\|ryP	NYPzXJZtW0GQR1XS
CFPAC-1	NFOzT3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGS1bnpKSzVyPUeuN\|YzOjJizszN	MVHTRW5ITVJ?
MG-63	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTFVoVjUUN3ME23MlQyQDR7IN88US=>	NV7OXpdYW0GQR1XS
KYSE-140	NIjJPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;GTWM2OD15LkS0NFYyKM7:TR?=	NX\TelN2W0GQR1XS
MPP-89	NXfRflRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLpV3ZKSzVyPUeuOVk4OjlizszN	NVzwTFAxW0GQR1XS
COLO-824	MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn2zTWM2OD15LkeyPFY{KM7:TR?=	MofyV2FPT0WU
SiHa	MoL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXRTWM2OD15LkizO\|A4KM7:TR?=	MXvTRW5ITVJ?
SNU-387	MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTdwOEWzOFch\|ryP	MUDTRW5ITVJ?
A172	M2TUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGD0Vo1KSzVyPUeuPFYyPzJizszN	Ml;XV2FPT0WU
COLO-680N	Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTdwOUG3N{DPxE1?	MlS1V2FPT0WU
HCC1395	M3jSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LzbmlEPTB;OD6wOVQ2OiEQvF2=	NVf3NlNCW0GQR1XS
NCI-H28	M1;NN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRThwMEW5OlMh\|ryP	M3Tpd3NCVkeHUh?=
LC-2-ad	M{\kdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjHclFKSzVyPUiuNlE6OzdizszN	NILrcYdUSU6JRWK=
S-117	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXw[YhKSzVyPUiuNlU{PTNizszN	MmTsV2FPT0WU
NCI-H1838	NEHXPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRThwMkW3PFEh\|ryP	M1;wbHNCVkeHUh?=
PANC-10-05	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRThwM{ewOFch\|ryP	NGXLUZNUSU6JRWK=
KALS-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzVbJVVUUN3ME24MlUxQTJ6IN88US=>	MVfTRW5ITVJ?
LS-1034	M2[zNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\3OoVKSzVyPUiuOVc1OzdizszN	MmPQV2FPT0WU
TGBC1TKB	NED6N5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmD5TWM2OD16LkezOVM2KM7:TR?=	NF3WVnNUSU6JRWK=
OE19	NGX4NFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3JUI0xUUN3ME24Mlc3OjZ{IN88US=>	NHntd4hUSU6JRWK=
D-502MG	Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVu2VGdPUUN3ME24Mlc3QTl2IN88US=>	M1XD[XNCVkeHUh?=
JEG-3	M3PGVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnWTWM2OD16Lke4OlE5KM7:TR?=	MUXTRW5ITVJ?
DBTRG-05MG	Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjwVWRKSzVyPUiuPFc2PjVizszN	MUPTRW5ITVJ?
ME-180	NFzM[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjVPFIyUUN3ME25MlA3PzJ3IN88US=>	M3\SbHNCVkeHUh?=
NCI-H1573	NEXYTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7HSnVDUUN3ME25MlExPTN{IN88US=>	NHzNR3NUSU6JRWK=
HCC2998	MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LoOWlEPTB;OT6xN\|Y5OSEQvF2=	M4XEe3NCVkeHUh?=
ACHN	M2H1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTlwMkS5O\|Uh\|ryP	NWLjTmlKW0GQR1XS
D-392MG	MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTlwMkW3NVUh\|ryP	MX\TRW5ITVJ?
no-11	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4Dlb2lEPTB;OT6yOlAzQCEQvF2=	MXjTRW5ITVJ?
KLE	NEPKXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLSTWM2OD17LkOyNlMzKM7:TR?=	Mn;NV2FPT0WU
Calu-6	M3ft[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTlwM{e1Nlgh\|ryP	NHztPWlUSU6JRWK=
LB831-BLC	M3HVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfiZnpJUUN3ME25MlQ2OTdzIN88US=>	MkHSV2FPT0WU
SW684	M{LLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLNRm1KSzVyPUmuOFYyOTZizszN	M2fFcXNCVkeHUh?=
SH-4	Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmf1TWM2OD17LkS5N\|Y1KM7:TR?=	M3jnWXNCVkeHUh?=
IST-MES1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LlNWlEPTB;OT61NVY1PCEQvF2=	MkfWV2FPT0WU
Saos-2	Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnrWYlpUUN3ME25MlUzOTl3IN88US=>	MYPTRW5ITVJ?
NCI-H2087	Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTle29KSzVyPUmuOlc{PTJizszN	MoP5V2FPT0WU
SCC-9	M{HacGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTlwN{G4NVYh\|ryP	M2XXNHNCVkeHUh?=
MFE-280	NF2yZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTCeFFVUUN3ME25MlczPzh3IN88US=>	MmmzV2FPT0WU
BEN	NEDSZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2Px[GlEPTB;OT64NlE2QSEQvF2=	MmnqV2FPT0WU
CP50-MEL-B	M4ewR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTlwOUK0N\|Ih\|ryP	MoLyV2FPT0WU
SK-MEL-28	NXv4NVNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLYdWFwUUN3ME2xNE4xOTl\|IN88US=>	MWrTRW5ITVJ?
NCI-H2452	M4XJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2LyO2lEPTB;MUCuNVYh\|ryP	NUHCeWU4W0GQR1XS
NCI-H1395	NYC3O2NTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mkm1TWM2OD1zMD6xO\|gh\|ryP	M{\hT3NCVkeHUh?=
NCI-H2052	M37jSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTFyLkG4PFIh\|ryP	MVnTRW5ITVJ?
A375	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jpRWlEPTB;MUCuNlQ2OiEQvF2=	M3fS[3NCVkeHUh?=
HCC38	NELJdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvIfIpKSzVyPUGwMlMzOiEQvF2=	MoHTV2FPT0WU
LK-2	MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTFyLkSyNFgh\|ryP	NGm2UXFUSU6JRWK=
SF126	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\a[ZczUUN3ME2xNE41PzJ5IN88US=>	M2rXOXNCVkeHUh?=
SK-MEL-1	M{f2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTFyLke4N\|gh\|ryP	MV\TRW5ITVJ?
ACN	M1jFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPITWM2OD1zMD64Olc6KM7:TR?=	MX\TRW5ITVJ?
BB30-HNC	NGe2dFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLBe2FRUUN3ME2xNE45PzFzIN88US=>	MnPDV2FPT0WU
NCI-H747	NHzGclZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXZeGV7UUN3ME2xNE45PzR4IN88US=>	NIDoe3NUSU6JRWK=
KYSE-150	M{fCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1m1TGlEPTB;MUGuNFM5PyEQvF2=	MnTNV2FPT0WU
D-247MG	M{eyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTFzLkGwNFkh\|ryP	NELFTW1USU6JRWK=
BxPC-3	NUW4PXd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnTTWdKSzVyPUGxMlM4PDdizszN	NYLndFV{W0GQR1XS
SK-MEL-30	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHu4clZKSzVyPUGxMlQxPzlizszN	MXrTRW5ITVJ?
CAS-1	NUnDVmhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTFzLkSxNFkh\|ryP	MlXUV2FPT0WU
no-10	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmD4TWM2OD1zMj6xNlE4KM7:TR?=	MUjTRW5ITVJ?
NCI-H2405	Mnr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXpbZdKSzVyPUGyMlIxOzZizszN	NESwSZZUSU6JRWK=
KGN	NH7EVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnwTWM2OD1zMj6yPVAyKM7:TR?=	NFrLTYVUSU6JRWK=
BB49-HNC	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjnN45KSzVyPUGyMlM6PTZizszN	MVrTRW5ITVJ?
NCI-H1693	NXT0T\|ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7jO\|hJUUN3ME2xNk42QDF4IN88US=>	MY\TRW5ITVJ?
RO82-W-1	M{HGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\ocFNKSzVyPUGzMlA3PDlizszN	NH;2WpBUSU6JRWK=
CAL-85-1	NV;N[pdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jPS2lEPTB;MUOuOFM6QSEQvF2=	MYHTRW5ITVJ?
H-EMC-SS	NWfsPZFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzWTWM2OD1zMz65NVA1KM7:TR?=	MX;TRW5ITVJ?
SW1783	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTF2LkKzPVEh\|ryP	NH3iblhUSU6JRWK=
LB771-HNC	NELFN3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUT6R\|hwUUN3ME2xOE41OTlizszN	MnfoV2FPT0WU
HCC70	M4\Kcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LzOWlEPTB;MUSuOFI{OyEQvF2=	NHz2OHZUSU6JRWK=
KNS-81-FD	NYTZPIxxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LTNmlEPTB;MUSuO\|A1PSEQvF2=	MlXKV2FPT0WU
KYSE-520	M32wOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTF2LkmyO{DPxE1?	MoTrV2FPT0WU
TGBC24TKB	NWLYcmRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjhV\|dKSzVyPUG0Mlk2OzlizszN	MV7TRW5ITVJ?
SNB75	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{foZmlEPTB;MUWuNFczQSEQvF2=	M2PYfXNCVkeHUh?=
SW872	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTF3LkKyNVgh\|ryP	M3XifXNCVkeHUh?=
U031	MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTUVIdKSzVyPUG1MlgxOjhizszN	M1LMe3NCVkeHUh?=
ChaGo-K-1	M3T3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYLHenZDUUN3ME2xOU45OzV7IN88US=>	NXHtdoZGW0GQR1XS
NCI-H441	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33kVmlEPTB;MU[uNFA{QSEQvF2=	NGD4ZZhUSU6JRWK=
TE-12	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTF4LkG4O\|Mh\|ryP	M3nYPHNCVkeHUh?=
NCI-H1755	NXTMfpl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF[yNFVKSzVyPUG2MlU4OyEQvF2=	MXPTRW5ITVJ?
KNS-42	M4\wdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTF4Lk[1PFkh\|ryP	M3PiTHNCVkeHUh?=
SK-PN-DW	M4XQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XTW2lEPTB;MUeuOFIxOSEQvF2=	NUjrdnM{W0GQR1XS
NCI-H226	MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rFTGlEPTB;MUeuPVM1PSEQvF2=	NU\LO3JPW0GQR1XS
K-562	NFfUSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XX[GlEPTB;MUiuOlMyPyEQvF2=	NIfYNnhUSU6JRWK=
A388	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljKTWM2OD1zOT6wN\|A{KM7:TR?=	NU\z[JZyW0GQR1XS
ZR-75-30	MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTYcIh3UUN3ME2xPU4xQTZ6IN88US=>	MX\TRW5ITVJ?
LU-135	NXrCZphWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jKdmlEPTB;MUmuNlY{PiEQvF2=	NFXjNZhUSU6JRWK=
NCI-H2029	NWX4[JJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7JTWM2OD1zOT62NFIyKM7:TR?=	MorYV2FPT0WU
HT-1197	MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfLblVKSzVyPUG5MlkzOjdizszN	Mm\SV2FPT0WU
IGR-1	NFv3RpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;VTWM2OD1{MD6zNVE4KM7:TR?=	NH;v[VRUSU6JRWK=
U-87-MG	NU\6VnNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVridphEUUN3ME2yNE43PDF\|IN88US=>	MnrEV2FPT0WU
NCI-H1304	MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmmwTWM2OD1{MD63OVAyKM7:TR?=	M17YN3NCVkeHUh?=
RCC10RGB	NYr0TYJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rZZWlEPTB;MkGuNlgzQSEQvF2=	NHXrV\|ZUSU6JRWK=
NCI-H520	M2\CSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzoe4hKSzVyPUKyMlc3OTFizszN	NHPUTVZUSU6JRWK=
SK-LU-1	NYjaTItXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnWW\|dKSzVyPUKzMlA4OThizszN	NFzYS4hUSU6JRWK=
UACC-893	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnVfo03UUN3ME2yN{4yODN6IN88US=>	M2mzTXNCVkeHUh?=
NCI-H2347	NGPsV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fkWGlEPTB;MkOuNlY4PCEQvF2=	NXzZ[2JSW0GQR1XS
U-118-MG	NHPI[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4OwdWlEPTB;MkOuO\|IyPyEQvF2=	NVK5dXJqW0GQR1XS
NCI-H596	M2XYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELp[5RKSzVyPUKzMlkxPTVizszN	NWrtdlB[W0GQR1XS
MZ1-PC	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zmT2lEPTB;MkSuOlc2QSEQvF2=	Mm\6V2FPT0WU
SW1417	NVPYU2F1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3wSIhKSzVyPUK1MlI1QThizszN	NUWzXWFbW0GQR1XS
NCI-H82	NX;IeYpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vMcWlEPTB;Mk[uOFI5QCEQvF2=	NG\VU5JUSU6JRWK=
COLO-678	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjKRW5KSzVyPUK3MlQ6OTlizszN	M2XhUnNCVkeHUh?=
KURAMOCHI	M{m4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPPO\|hUUUN3ME2yPE4yOjZizszN	MXLTRW5ITVJ?
NCI-H1650	MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;LW2lEPTB;M{CuNVkzPCEQvF2=	MXLTRW5ITVJ?
HCC1954	NUnmVJQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjKTGJpUUN3ME2zNU4{PjZ4IN88US=>	NHjRW3dUSU6JRWK=
GAK	NIL1dWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjuTo1KSzVyPUOyMlI3OTZizszN	NGX3Z25USU6JRWK=
YAPC	M2qxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1n1NGlEPTB;M{OuO\|Y1QCEQvF2=	MkfTV2FPT0WU
NCI-H2228	NXzFR2tRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXn3SFBSUUN3ME2zOE4{PjB3IN88US=>	NEC0dXdUSU6JRWK=
VMRC-RCZ	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7vT2RjUUN3ME2zOk4{ODJ{IN88US=>	NGLFPHJUSU6JRWK=
NMC-G1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rROmlEPTB;M{euNFUzQSEQvF2=	NF\sXpBUSU6JRWK=
D-336MG	NXvRcnZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrnTWM2OD12MT64OFQzKM7:TR?=	NFvpbnBUSU6JRWK=
UACC-62	MlrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTR{LkW1NFUh\|ryP	NE\I[\|NUSU6JRWK=
C-33-A	NWT2SXQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFOweItKSzVyPUS1MlMzPTZizszN	MXXTRW5ITVJ?
HCC1937	M3r6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzVbFRKSzVyPUS3MlE6PThizszN	MYrTRW5ITVJ?
HDLM-2	NXzsOWdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPWSYhKSzVyPUS3MlIzQDdizszN	NGK4TIJUSU6JRWK=
NCI-H727	NF\mc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXj3Vpo{UUN3ME20O{4zPDVzIN88US=>	Mn\6V2FPT0WU
NY	NV74VWJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rON2lEPTB;NEmuN\|kxQCEQvF2=	M1fZZnNCVkeHUh?=
NCI-H2291	NXfzeoFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVK4OmI6UUN3ME20PU45OzBzIN88US=>	NIHUdmpUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo

Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. ^[2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. ^[5]

Protocol

Kinase Assay: ^[1]	+ Expand Immunoprecipitation-HDAC assays: The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an ³H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [³H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research: ^[2]	+ Expand Cell lines: LNCaP, PC-3, and TSU-Pr1 Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM Incubation Time: 1, 2, 3 and 4 days Method: Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion. (Only for Reference)
Animal Research: ^[2]	+ Expand Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells Formulation: Dissolved in DMSO Dosages: ~100 mg/kg/day Administration: Injection i.p. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	52 mg/mL (196.74 mM)
	Ethanol	3 mg/mL (11.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Molecular Weight	264.3
Formula	C₁₄H₂₀N₂O₃
CAS No.	149647-78-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SAHA, MK0683, suberoylanilide hydroxamic acid

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03742245	Not yet recruiting	Breast Cancer Metastatic\|Breast Cancer	Jenny C. Chang MD\|AstraZeneca\|The Methodist Hospital System	March 1 2019	Phase 1
NCT03022565	Recruiting	Uveal Melanoma	University of Miami\|University of Miami Sylvester Comprehensive Cancer Center	December 2018	Early Phase 1
NCT03263533	Recruiting	Schizophrenia	Virginia Commonwealth University	December 1 2018	Early Phase 1
NCT03259503	Not yet recruiting	Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic\|Lymphoma	M.D. Anderson Cancer Center\|AstraZeneca	November 2018	Phase 1\|Phase 2
NCT03713320	Recruiting	Cutaneous T-Cell Lymphoma/Mycosis Fungoides	miRagen Therapeutics Inc.	October 2018	Phase 2
NCT03382834	Active not recruiting	HIV Infections	National Institute of Allergy and Infectious Diseases (NIAID)	April 26 2018	Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products5

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 103 Publications

20 Customer Reviews

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 103 Publications

20 Customer Reviews

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)